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ABSTRACT 
BACKGROUND 
New sources of insulin-secreting cells are strongly required for the cure of diabetes. 
Recent successes in differentiating embryonic stem cells, in combination with the 
discovery that it is possible to derive human induced pluripotent stem cells (iPSC) from 
somatic cells, have raised the possibility that patient-specific ? cells might be derived 
from patients through cell reprogramming and differentiation.  
AIMS 
In this study, we aimed to obtain insulin-producing cells from human iPSC and test 
their ability to secrete insulin in vivo. 
METHODS: 
Human iPSC, derived from both fetal and adult fibroblasts, were differentiated in vitro
into pancreas-committed cells and their ability to secrete insulin was measured. iPSC-
derived cells at two different stages of differentiation (posterior foregut and endocrine 
cells) were transplanted into immunodeficient mice to test their ability to engraft, 
differentiate and secrete insulin.  
RESULTS: 
IPSC were shown to differentiate into insulin-producing cells in vitro, following the 
stages of pancreatic organogenesis. At the end of the differentiation, the production of 
INSULIN mRNA was highly increased and up to 14% of the cell population became 
insulin-positive. Terminally differentiated cells also produced C-peptide in vitro in both 
basal and stimulated conditions. In vivo, mice transplanted with pancreatic cells secreted 
human C-peptide in response to glucose stimulus, but transplanted cells were observed 
to lose insulin secretion capacity during the time. At histological evaluation, the grafts 
were composed of a mixed population of cells containing mature pancreatic cells, but 
also pluripotent cells and rare neuronal cells. 
CONCLUSION: 
These data overall suggest that human iPSC have the potential to generate insulin-
producing cells and that these differentiated cells can engraft and secrete insulin in vivo. 
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I. ACRONYMS AND ABBREVIATIONS 
iPSC: induced Pluripotent Stem Cells 
WHO: World Health organization 
T1D: Type 1 Diabetes 
HbA1c: Glycated Hemoglobin 
CITR: Collaborative Islet Transplant Registry 
GH: Growth Hormone 
GLP-1: Glucagon-like Peptide 1 
HGF: Hepatocyte Growth Factor 
Pdx-1: Pancreatic and duodenal homeobox 1 
Gal: Galactose ?1,3Galactose 
PERV: Porcine Endogenous Retrovirus 
ESC: Embryonic Stem Cells 
HSC: Hematopoietic Stem Cells 
MSC: Mesenchymal Stem Cells 
GFP: Green Fluorescence Protein 
FGF-?: Fibroblast Growth Factor-?
EGF: Endothelial Growth Factor 
PKC: Protein Kinase C 
TGF?: Transforming Growth Factor ?
MEFs: Murine Fetal Fibroblasts 
bFGF: basic Fibroblast Growth Factor 
AMD: Age-related Macular Degeneration 
HLA: Human Leucocyte Antigen 
FBS: Fetal Bovine Serum 
DE: Definitive Endoderm 
PG: Primitive Gut Tube 
CYC: KAAD-Cyclopamine 
PF: Posterior Foregut 
GLP-1: Glucagon-like peptide-1 
DAPT:  N-[N-(3,5-Difluorophenacetyl)-L-alanyl] -S-phenylglycine t-butylester 
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NGN3: Neurogenin3 
EN: Hormone-expressing Endocrine 
IGF-1: Insulin-like growth factor 1 
HGF: Hepatocyte growth factor 
IL V: Indolactam V 
EB: Embryoid Bodies 
AU: Arbitrary Units 
SeV: Sendai Virus  
ME: Mesendoderm 
PE: Pancreatic Endoderm 
BM: Basal Medium 
BSA: Bovine Serum Albumin 
KGF: Keratinocyte Growth Factor 
ITS: Insulin-Transferrin-Selenium 
PdBU: Phorbol 12,13-dibutyrate 
T3: L-3,3’,5-Triiodothyronine 
ddPCR: Droplet Digital PCR 
DAVID: Database for Annotation, Visualization and Integrated Discovery 
FDR: False Discovery Rate 
FACS: Fluorescence-activated cell sorting 
ELISA: Enzyme-Linked Immunosorbent Assay
OGTT: Oral Glucose Tolerance Test 
AP: Alkaline Phosphatase 
FC: Fold Change 
SEM: Standard Error of the Mean 
IBMX: phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
KCl: potassium chloride 
SSC: Side Scatter 
APC: Allophycocyanin 
PE: phycoerythrin 
MODY: Maturity onset diabetes of the young 
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II. INTRODUCTION 
1. Type 1 Diabetes 
In 2014 The World Health Organization (WHO) estimates that there were 387 million 
people suffering from diabetes worldwide, a number that is predicted to increase to 592 
million by 2035 (Whiting et al., 2011). Approximately 10% of these cases are of type 1 
diabetes (T1D) (Stanekzai et al., 2012), a disease characterized by an absolute 
deficiency of insulin-producing pancreatic ?-cells caused by an autoimmune-mediated 
destruction.
Administration of exogenous insulin, regular blood glucose monitoring and dietary 
restrictions are the fundamental means of treating hyperglycemia in all patients with 
T1D. Although life-saving, insulin therapy does not restore the physiological regulation 
of blood glucose and is not able to prevent either the dangerous states of hypoglycemia 
or long-term complications like ketoacidosis, kidney failure, cardiovascular diseases, 
neuropathy and retinopathy (van Belle et al., 2011). Despite new technologies like 
slow-release insulin or insulin pumps have been developed in the last years and have 
substantially improved glycemic control as well as the quality of life of diabetic patients 
(Saudek et al., 2013), a fail-safe physiological regulation of systemic blood glucose 
levels remains challenging. The only possible definitive cure for this disease consists in 
providing a new ? cell source capable of performing two essential functions: assessing 
blood sugar levels and secrete insulin in a glucose-dependent manner. 
2. ? cell replacement with ? cells  
2.1 Allogeneic adult cells  
At present, only pancreas or islet transplantation offer an alternative treatment option 
through restoration of the physiological response to changes in blood glucose levels. 
Whole pancreas transplantation is very effective in achieving insulin independence and 
in maintaining long-term physiological glycemic control: currently, graft survival for 
pancreas transplants alone is 82% at 1 year and 58% at 5 years, and these numbers are 
increased to 89% and 71% respectively for dual pancreas and kidney transplants 
(Redfield et al., 2015). However, because of the significant morbidity associated with 
this major surgery, this therapeutic approach is almost exclusively limited to diabetic 
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patients who also suffer for end-stage renal disease undergoing a simultaneous kidney 
transplant (Ichii & Ricordi, 2009). By contrast, islet transplantation requires a 
minimally invasive surgical procedure in which islet preparations are infused into the 
recipient liver through the portal vein, using a percutaneous radiologic procedure 
(Venturini et al., 2005). A functional transplant in a T1D patient can eliminate 
hypoglycemic episodes, correct glycated hemoglobin (HbA1c), reduce or reverse risk of 
secondary complications associated with the disease and, in the best cases, lead to 
insulin independence achievement (Barton et al., 2012). The first attempt of an islets 
transplant as a treatment for diabetes could be considered that of Dr. Watson-Williams 
and Dr. Harshant in 1893, when they transplanted small fragments of a sheep pancreas 
into a young patient with diabetic ketoacidosis who died after few days (Williams et al., 
1894). In this case, no attempt to purify the islets was performed. The first evidence of 
the effectiveness of islet isolation and transplantation was reported only in 1972 by 
Ballinger and Lacy in chemically induced diabetic rats (Ballinger & Lacy, 1972), with 
Kemp et al. establishing the liver as the most suitable site for islet implantation (Kemp 
et al., 1973). Five years later the first islet infusion in human was performed, with 
azathioprine and corticosteroid as immunosuppressive drugs (Najarian et al., 1977). 
Since then, many efforts and significant progress have been achieved in the field of islet 
transplantation, in terms of human islets isolation (Ricordi et al., 1988), 
immunosuppression strategies (Oberholzer et al., 2000; Hering et al., 1994) and optimal 
number of transplanted islets per kilograms of body weight (Secchi et al., 1997). The 
knowledge deriving from these experiences led to the appearance in 2000 of the 
“Edmonton protocol”, that was then adopted by all the centers of islet transplantation in 
the world; that year indeed Shapiro et al. published a success rate of 100% at 1 year in 
seven out of seven consecutive T1D patients, introducing several novelties to the 
procedures, above all the use of a glucocorticoid-free immunosuppressive regimen 
(Shapiro et al., 2000). Since then, the outcomes and safety of human islet allografts 
have steadily improved through the past few years. As recently reported by the 
Collaborative Islet Transplant Registry (CITR), insulin independence at 3 years after 
transplant improved from 27% in the early era (1999–2002) to 37% in the middle phase 
(2003–2006) and to 44% in the most recent era (2007–2010) (Barton et al., 2012). 
Moreover, five independent centers (Edmonton, Minnesota, Geneva, Milan and Lille) 
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are reporting a 5-year rate of insulin independence exceeding 50% (Shapiro et al., 
2011), closely matching the results of pancreas-alone transplantation from the 
International Pancreas Transplant Registry. Islet transplantation is currently being fully 
reimbursed under non-research, clinical care streams in several countries including 
Canada, United Kingdom, Sweden and the Nordic Network, Swiss and Australia. At 
present however, islet transplantation is far from being a standard procedure because of 
two main problems: the need for lifelong immunosuppression (with multiple adverse 
side-effects) and the lack of pancreases from heart-beating brain-dead donors (the only 
suitable source of human islets for clinical use). For these reasons, islet transplantation 
is presently restricted to diabetic patients showing unexplained metabolic instability 
despite carefully monitored insulin therapy, complicated by recurrent hypoglycemic 
events (Bertuzzi et al., 2007).  
In this scenario, a novel strategy to address the problem of how to reconstitute 
pancreatic endocrine function in diabetic patients is clearly needed. Many approaches 
are currently being studied intensively, in particular ? cell proliferation/regeneration, 
xenotransplantation and differentiation of pluripotent stem cells (Figure 1).  
Figure 1. The most promising sources and the related strategies currently studied in order to obtain a 
large amount of transplantable ? cells. Pellegrini, 2013. 
11 
2.2 Autologous cells (? cell proliferation or trans-differentiation in vivo/ex vivo) 
Unlike blood, skin or intestine, that are tissues with a relatively rapid turnover of cells, 
β cells in the pancreatic islets are a quiescent population with a proliferative ratio of 
0,1-0,3%/day in 1-year-old mice (Teta et al., 2005). Recent studies, however, have 
shown that also β cells mass is regulated dynamically and the relation between 
replication and apoptosis can determine the final mass (P. C. Butler et al., 2007; Lipsett 
et al., 2006). In human, normal expansion of the β cell mass occurs during the neonatal 
period, but fades early in childhood (Meier et al., 2008); in adult, β cell replication 
resulted increased in some physiological or pathological states, such as pregnancy 
(Parsons et al., 1995) or an obesity-induced insulin-resistant state (Gupta et al., 2007). 
Thus, the use of external agents to expand β cells ex vivo for transplantation purpose or 
to stimulate endogenous cell proliferation in vivo in order to increase the β cells mass in 
diabetic patients may be an attractive approach for β cells supplementation. In fact, β
cell regeneration has been observed also in T1D patients after onset (Willcox et al., 
2010) or even many years after diagnosis (Pipeleers & Ling, 1992; Keenan et al., 2010). 
Moreover, Dor et al. in a lineage-tracing study in mice observed a dramatic increase in 
β cell mitotic index following pancreatic injury such as 50~70% pancreatectomy (Dor 
et al., 2004) or a selective β cell genetic ablation (Nir et al., 2007). Transfection of 
many cell cycle regulators like cdks (cycline dependent kinases) and cyclins into rodent 
and human islets ex vivo, leads to an increase in the replication rate of β cells (Cozar-
Castellano et al., 2004; Fiaschi-Taesch et al., 2010), but the prolonged expression of 
these molecules would increase also the risk of oncogenesis. A safer option is 
represented by the addition in culture of growth factors, such as growth hormone (GH), 
glucagon-like peptide-1 (GLP-1) or hepatocyte growth factor (HGF), that have been 
described to increase the replication rate of rodent β cells (Nauck et al., 1993); 
unfortunately, in human the elevated proliferation is associated with a loss of β cell 
features, like Pdx-1 or insulin expression (Parnaud et al., 2008). An in vivo therapy with 
long-acting GLP-1 analogues (exenatide or liraglutide) has been considered to have a 
potential for the stimulation of β cell replication in diabetic patients after proof-of-
concept studies performed in patients treated with GLP-1 (Nauck et al., 1993; Rachman 
et al., 1997), but long-term data of the evidence of such increase in patients have yet to 
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be provided. In the field of β cell proliferation, a gene therapy aimed at the reversible 
inclusion of genes capable of immortalizing β cells has been tried as well. During the 
past 30 years, a number of ? cell lines have been established in rodent (Gazdar et al., 
1980; Hohmeier & Newgard, 2004) and many attempts have been made to generate 
human ? cell lines from many pancreatic sources, but insulin production by these cells 
was extremely low or limited at few passages (Levine et al., 1995; de la Tour et al., 
2001). In 2005, Narushima et al. reported the successful establishment of a functional 
human ? cell line, NAKT-15, that looked promising for cell therapy of diabetes, but no 
new reports on the utility of this line have been published since 2005 (Narushima et al., 
2005). In 2011 another human ? cell line was established transducing human fetal 
pancreases with a lentiviral vector that expressed SV40LT and human telomerase 
reverse transcriptase (hTERT). One of the cell lines generated with this strategy, the 
EndoC-?H1, was further characterized and resulted able to secrete insulin in response to 
glucose stimulation, was stable at least for 80 passages and expressed many specific ?
cell markers, without any substantial expression of markers of other pancreatic cell 
types (Ravassard et al., 2011). In view of clinical use, a second generation of human ?
cell lines has been recently developed; the conditionally immortalized EndoC-?H2 cell 
line is based on Cre-mediated excision of the immortalizing transgenes, leading to an 
arrest of cell proliferation and pronounced enhancement of ? cell–specific features such 
as insulin expression, content, and secretion (Scharfmann et al., 2014), but further 
studies are required to determine the actual safety of these cells.  
Another completely different point of view is the theory that neogenesis and not 
proliferation is the mechanism responsible for β cells-mass expansion in conditions like 
pregnancy or obesity. A recent autopsy study on human pancreata during or after 
pregnancy supports this hypothesis: Butler et al. observed the presence of more new 
small islets rather than an increase in β cell replication, islet size or change in apoptosis 
(Butler et al., 2010). They also observed an increased number of insulin positive cells 
within ducts, indicating that duct cells can differentiate in β cells in certain conditions or 
that pancreatic stem/progenitor cells are localized in pancreatic ducts. In previous works 
putative pancreatic stem cells have been localized also in exocrine cells and endocrine 
islets, suggesting a widespread distribution within the pancreas and that a precise 
characterization of these cells still lacks (Jones et al., 2008). Experiments of 90% 
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pancreatectomy in rats show the substantial regenerative capacity of the adult pancreas 
(Dor et al., 2004; Bonner-Weir et al., 1993) and in a recent work it was demonstrated 
that this regeneration follows a dedifferentiation-redifferentiation paradigm, in which 
mature duct cells dedifferentiate to a progenitor-like state and then differentiate to form 
all pancreatic cell types, including β cells (Li et al., 2010). Also in this work an 
increased proliferation rate of the remaining β cells was observed, indicating that 
replication and neogenesis are not mutually exclusive and they both contribute to 
maintain an adequate β cell mass after birth, but there are important differences in the 
balance of these two pathways depending on species and age (Bonner-Weir et al., 
2010). The potential of α cells as possible source of insulin-producing cells has also 
been explored, since these cells are preserved in diabetic patients (Gianani et al., 2011) 
and are the most abundant endocrine cells in islets other than β cells. Collombat and 
colleagues have shown that the ectopic expression of Pax4 could force mature α cell 
conversion to β cells, reversing chemically induced diabetes in mice (Collombat et al., 
2009). In addition, Thorel et al. confirmed the differentiation potential of α cells 
reporting their spontaneous conversion to new functional β cells using a selective 
diphtheria toxin-mediated β cells ablation model (Thorel et al., 2010). Whether this 
plasticity might exist in human is unknown, but experiments in chemically-induced 
diabetes in non-human primate didn’t show evidence of β cells regeneration (Saisho et 
al., 2011). 
2.3 Xenogeneic cells
Using islets of Langerhans derived from other species seems an obvious way of 
providing the large amount of islets required for transplantation therapy of diabetes. 
Most effort in this area has been directed towards the use of pig islets for many reasons: 
(i) porcine pancreas as a by-product of pork production has been used for years as an 
exogenous source of insulin before recombinant human insulin became available, (ii) 
porcine islets regulate glucose levels in the same physiologic range as humans, (iii) high 
islets yields can be obtained with techniques similar to those for human islet isolation 
and (iv) pigs can be genetically modified for making their islets more suitable for 
human transplantation (Klymiuk et al., 2010). Recent studies in nonhuman primates 
reported the long-term survival of neonatal (Cardona et al., 2006) or adult (Hering et al., 
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2006) porcine islets in the presence of immunosuppression therapy and/or adoptive 
transfer of expanded autologous regulatory T cells (Shin et al., 2015). Two main 
problems have however limited the use of pig islets in humans. First, the risk of an 
hyperacute immunologic rejection, because humans have natural preformed antibodies 
that react to a saccharide, Galactose ?1,3Galactose (Gal) expressed on cells of lower 
mammals but not on cells of humans or monkeys (Galili et al., 1988): the binding of 
antibodies to Gal antigens results in almost an immediate complement activation, with 
consequent destruction of the graft. Second, the risk of zoonosis because porcine 
endogenous retroviral (PERV) sequences can infect several human cells in vitro
(Patience et al., 1997; Wilson et al., 1998) and may be activated after the xenotransplant 
(van der Laan et al., 2000). A strategy currently studied in order to overcome the 
problem of the immunogenicity of pig cells consists in islets microencapsulation; the 
cells can be enveloped within a biocompatible membrane (often of barium alginate) 
and, due to the molecular weight cutoff of the capsule material, cells are isolated from 
the host immune system (Rayat et al., 2000). Studies in both non-human-primate 
(Dufrane et al., 2010) and human recipients (Elliott et al., 2007) without 
immunosuppressive drugs were performed and, despite promising results, whether 
encapsulated islets will survive and function for long periods in human is unknown. 
Currently, two clinical trials using encapsulated porcine islets are ongoing in New 
Zealand (DIABECELL®) and in Russia and their findings are expected to be published 
imminently. No subjects, to our knowledge, have been rendered insulin free with such 
approaches to date (Moore SJ, 2015). In summary, encouraging results in extending the 
survival and the safety of transplanted pig islets have recently been obtained, but several 
issues must still be addressed and this strategy is far from an ideal option. 
3. ? cell replacement with non ? cells  
Currently, many opportunities for the cell therapy of single-cell disorders like diabetes 
are offered by stem cell differentiation. Stem cells are, by definition, undifferentiated 
cells that hold both the potential to differentiate into a large variety of specialized cell 
type and the ability to go through numerous cycles of cells division while maintaining 
their undifferentiated state (self-renewal). In mammals, there are two broad types of 
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stem cells: Embryonic stem cells (ESC), which are isolated from the blastocysts, and 
adult stem cells, which are found in various tissues (Calafiore & Basta, 2015). 
3.1 Adult stem cells  
Adult stem cells are multipotent progenitors that, by definition, can differentiate only in 
certain types of specialized cells, and are deputed to the maintenance, repair and 
reconstitution of the tissue in which they are found. For many years these cells were 
considered to be able to differentiate only in cells of the tissue/organ of origin, but 
subsequently it has been shown that adult stem cells can trans-differentiate into cells of 
other tissues (Davis et al., 1987). This opened the way for the use of stem cells of 
different types of tissues as a source of progenitor cells potentially able to become an 
autologous source of insulin-secreting cells. Since the identification of pancreatic stem 
cells is still controversial (Dor et al., 2004; Jiang & Morahan, 2014), many studies have 
focused their efforts on the use of bone marrow-derived stem cells, in particular 
hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC), as they are easily 
accessible and hold a remarkable cellular plasticity. In an initial study the ability of 
bone marrow stem cells to localize into pancreatic islets in vivo and to differentiate into 
insulin-expressing cells was demonstrated (Ianus et al., 2003), but this has not been 
confirmed by other groups. For instance, using GFP transgenic mice as donors, two 
groups evaluated the distribution of HSC in the pancreas after bone marrow 
transplantation and found that none of GFP-positive cells localized in islet or around the 
ducts expressed insulin, even after pancreatic injury (Choi et al., 2003; Lechner et al., 
2004). In humans, a study analyzed 31 human pancreata obtained at autopsy from HSC 
transplant recipients who had received their transplant from a donor of the opposite sex, 
and no contribution of HSC to endocrine pancreas was observed (Butler et al., 2007). 
These studies support the hypothesis that trans-differentiation of bone marrow cells is 
not a significant mechanism for adult pancreatic ? cell renewal. In addition, one study 
demonstrated that cell fusion rather than differentiation lies at the root of many 
processes of apparent bone marrow differentiation into ectodermal or endodermal 
tissues (Terada et al., 2002). In vitro multiple strategies involving exposure to various 
growth factor combinations under specific culture conditions, often augmented by 
genetic manipulation, were explored in order to differentiate HSC into insulin-
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producing cells but, at this time, consensus exists that MSC but not HSC can be induced 
to exhibit pancreatic properties (Ciceri & Piemonti, 2010). Several studies reported, 
after the treatment with defined combinations of growth factor, the appearance of 
insulin mRNA in cultures of MSC derived not only from bone marrow but also from 
adipose tissue or cord blood cells (Timper et al., 2006; Thatava et al., 2006; Sun et al., 
2007; Karnieli et al., 2007; Hisanaga et al., 2008; Chang et al., 2008; Xie et al., 2009; 
Bhandari et al., 2011; Dave et al., 2014; Qu et al., 2014). To give an example, recently a 
study was published about the differentiation of MSC into ? cells with a differentiation 
protocol of 18 days which includes the addition of FGF-?, EGF, Activin A and ?-
cellulin. Differentiated cells formed cell clusters some of which resembled pancreatic 
islet, stained positive with dithizone and were able to produce C-peptide (Czubak et al., 
2014). The limits of this and of many studies published before is that, at a deeper look, 
none of these differentiated cells exhibit the necessary conditions to be defined as ?
cells: insulin secretion in response to glucose stimuli and capacity to normalize 
glycemia in diabetic animal models. Moreover, safety is an issue when stem cells are 
forcedly converted in another cell type. For instance, in a study by Tang et al. islet-like 
MSC-derived cells expressed multiple genes related to islet development and ? cell 
function, produced insulin, demonstrated time-dependent glucose-stimulated insulin 
release, and the ability to ameliorate hyperglycemia in chemically induced diabetic 
mice, but, when transplanted into diabetic immunocompromised mice, differentiated 
cells became tumorigenic (Tang et al., 2012). Recently, multiple studies supported the 
differentiation capacity into insulin-producing phenotypes also of other adult extra-
pancreatic stem cell populations, like cells derived from liver, intestine, spleen, brain, 
dermis and mouse salivary glands (Limbert et al., 2008), but these studies have not 
proven to be reproducible. In conclusion, many tissues offer the possibility to derive 
progenitor cells able to differentiate into pancreatic beta-like cells, but until now none 
of the sources analyzed has proved to be capable of producing clinical-grade material, 
because of problems related to restricted proliferative capacity, low levels of insulin 
expression and poor, or non-existent, insulin secretion (Jones et al., 2008). 
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3.2 Embryonic stem cells 
Embryonic stem cells (ESC) are considered to be the most promising source of cells for 
cell/organ replacement therapies due to their virtually endless proliferative capacity and 
their potential to differentiate into cells of all the three embryonic germ layers 
(pluripotency). Therefore, the development of ESC lines from the inner cell mass of 
early stage mouse embryos (Evans & Kaufman, 1981; Martin, 1981) and, 17 years later, 
human embryos (Thomson et al., 1998) offered the potential to generate any specialized 
cell type in large quantities, including insulin-producing cells. Initially Soria et al. 
observed that undifferentiated ESC are able to naturally express insulin, so they tried to 
select these cells using a technique called "cell-trapping" (transfecting the cells with a 
chimeric construct which couples insulin gene with a gene that confers drug resistance) 
and directed their differentiation by modulating culture conditions to obtain a ? cell-like 
phenotype. The cells generated were able to secrete insulin in vitro in response to 
various stimuli but not to glucose (Soria et al., 2000). One year later another group 
developed an alternative approach, which consists in generating insulin-positive cells 
from murine Nestin-positive ESC colonies; Nestin is expressed in developing neurons, 
and islet and neural cells share phenotypic similarities (Zulewski et al., 2001). This type 
of approach led to the formation of cells capable of co-expressing all kinds of hormones 
produced by the cells in the pancreatic islets, but the final insulin content was very low
(Lumelsky et al., 2001). Further progress has been made after the identification of  the 
developmental cues that could induce ESC to replicate key aspects of the segregation of 
specific germ layers, as occurs during gastrulation in the normal embryo; since the 
pancreas is an endoderm-derived tissue, an important turning point was the induction of 
differentiation of ESC first into mesendoderm (progenitor of both endoderm and 
mesoderm), and subsequently into definitive endoderm (distinct from the 
extraembryonic visceral endoderm, which appears earlier and does not contribute to 
adult organ structures) (D’Amour et al., 2005). A major step forward came when the 
same group continued in a stepwise fashion to identify culture conditions and  
developmental signals that induce pancreatic organogenesis in vivo, in order to drive in 
vitro the further differentiation of human ES cell-derived definitive endoderm cells 
through subsequent stages on the desired path: posterior foregut, pancreatic endoderm, 
progenitors of endocrine pancreas and, finally, hormone-producing endocrine cells. 
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With their five-steps differentiation protocol the Baetge group (from Novocell, Inc., a 
preclinical stage stem cell engineering company focused on diabetes, that in 2010 
changed its name into ViaCyte, Inc) succeeded to obtain from human ESC about 7% of 
cells that expressed high levels of proinsulin that was processed, albeit inefficiently, to 
insulin and C-peptide. Insulin secretion was not responsive to glucose levels, but could 
be increased by other compounds known to act on ?-cells in fetal pancreas, which also 
respond poorly to glucose (D’Amour et al., 2006). Two other groups, using different 
culture conditions, confirmed that ESC are able to differentiate in insulin-producing 
cells, albeit with a lower efficiency (W. Jiang et al., 2007; J. Jiang et al., 2007). 
Subsequently Baetge and colleagues improved their results, optimizing their 
differentiation protocol and transplanting ESC-derived pancreatic progenitor cells into 
mice such that after three months in vivo the implanted cells differentiate into mature 
endocrine cells that can regulate blood glucose levels after diabetes induction (Kroon et 
al., 2008). They also identified CD142 (Tissue Factor) as a novel surface marker for the 
selection of pancreatic progenitor cells obtained through the differentiation of ESC; 
CD142+ cells transplanted in vivo give rise to all the pancreatic lineages, including 
functional insulin-producing cells (Kelly et al., 2011). The same group recently 
developed a scalable and standardized system for the production of functional 
pancreatic progenitors from human ESC, further optimizing their differentiation 
protocol for the CyT49 ESC line (Schulz et al., 2012). Finally, October 29th, 2014 
Viacyte announced the beginning of a Phase 1/2 clinical trial and that the first patient of 
this study was successfully implanted with ESC-derived insulin-producing cells 
delivered under the skin in a proprietary device with a selectively porous cell-
impermeable membrane, called the Encaptra® drug delivery system; this device is 
designed to protect the implanted cells from possible immune rejection, to permanently 
contain the cells and prevent their distribution away from the implantation site, and to 
provide a platform for product vascularization. This is the first time that an embryonic 
stem cell-derived cell replacement therapy for diabetes is studied in human subjects, 
and it represents the culmination of a decade of effort by the ViaCyte team 
(http://viacyte.com). Meanwhile, modified or improved protocols have been established 
using combinations of cytokines and small molecules, such as many Fibroblast Growth 
Factors, Sonic hedgehog pathway inhibitors (KAAD-cyclopamine or SANT-1), 
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Retinoic Acid, Nicotinamide, protein kinase C (PKC) activator (Indolactam V) or TGF?
pathway inhibitors (Alk5 inhibitor, Dorsomorphin or Noggin) (Chen et al., 2009; Ameri 
et al., 2010; Mfopou et al., 2010; Nostro et al., 2011a; Xu et al., 2011; Rezania et al., 
2012; Rezania et al., 2013; Nostro et al., 2015). Noteworthy are in particular the 
directed differentiation strategies reported by the research units of Melton and Kieffer 
(Pagliuca et al., 2014; Rezania et al., 2014). These two groups reported a novel and 
efficient approach to generate in vitro 20%–50% insulin (C-peptide)-positive cells from 
hESCs. Upon transplantation into immunocompromised mice, the graft (composed of 
endocrine and ductal cells) restored glycemia within 2 (Pagliuca et al., 2014) or 6 weeks 
(Rezania et al., 2014) after transplantation, a tremendous improvement compared with 
the 2-3 months period required after transplantation of hESC-derived pancreatic 
progenitors (Kroon et al., 2008). Nevertheless, the similarities and differences between 
?-like cells generated by all these groups remain to be elucidated by a direct 
comparison. Despite significant successes, three main problems still limit the use of 
ESC-derived insulin-producing cells. First, due to their pluripotency, undifferentiated 
cells give rise to teratoma formation in vivo and the transplantation of unselected 
differentiated cells would inevitably lead to tumorigenesis because of the presence of 
some residual undifferentiated cells (Kroon et al., 2008); several attempts have been 
made to identify surface markers able to select pancreatic progenitor cells (Kelly, Chan, 
L. A. Martinson, et al., 2011; Jiang et al., 2011) or to eliminate only pluripotent cells 
(Ben-David et al., 2013), but the safety of the selected cells requires further 
investigation. Another unsolved problem is related to the evidence that each ESC cell 
line has a different propensity to give rise to pancreatic cells (Osafune et al., 2008). 
Therefore many cell lines have to be tested (and, accordingly, the differentiation 
protocol must be optimized) in order to identify a set of ESC lines that could facilitate 
genetic matching of donor cells to patients and therefore prevent graft rejection and life-
long immunosuppression. The last major problem, which greatly limits the use of ESC 
in many countries of the world, is the presence of ethical concerns regarding the 
destruction of human embryos for the production of these cell lines. 
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4. Induced pluripotent stem cells 
4.1 Definition and characterization 
Because of their self-renewal abilities and the capacity to differentiate into any cell of 
the body, ESC have always been considered the most promising source for cell 
replacement therapies; despite this, however, their controversial origin and the 
impossibility to perform autologous therapies, had so far limited their use in clinical 
practice. To overcome these obstacles and still obtain pluripotent cells, the only possible 
way appeared to be the reprogramming of somatic cells to a state of embryonic-like 
stem cells. Initially, the reprogramming process of somatic cells has proved possible 
only transferring the nuclear content of these cells into oocytes (Wilmut et al., 1997) or 
fusing them with ESC (Tada et al., 2001). The results obtained from these experiments 
led many researchers to believe that the oocytes and ESC contain factors able to confer 
characteristics of pluripotency to somatic cells. The group of Yamanaka and colleagues 
in particular speculated that the elements capable of cover this important role in 
reprogramming induction were those involved in the maintenance of the 
undifferentiated state of ESC; to identify these factors they selected 24 candidate genes 
encoding for proteins that play an important role in maintaining cell identity of ESC and 
in their proliferation, including transcription factors (such as Oct3/4, Sox2, Nanog) or 
genes that are frequently overexpressed in tumors (such as Stat3, E-Ras, C-myc or 
Klf4), and tested their ability to reprogram somatic cells to pluripotent cells. They first 
transfected murine fetal fibroblasts (MEFs) with retroviral vectors containing the genes 
coding for 24 proteins of interest and observed the generation of colonies of embryonic-
like stem cells; later, in order to identify which of these 24 genes were necessary and 
sufficient to reprogram somatic cells, they monitored the formation of colonies by 
combining the transfection of the various factors among them. Using this strategy in 
2006 Prof. Yamanaka (winner of the Nobel prize in 2012 for this discovery) and his 
team found a set of four genes that, when over-expressed in murine fibroblasts (both 
embryonic and adult), are able to reprogram these somatic cells to pluripotent cells 
capable of self-renewal. This four reprogramming factors (also known as “Yamanaka’s 
factors”) are: 
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- POU domain class 5 transcription factor 1 (POU5F1), also known as Octamer-
binding transcription factor 4 (OCT3/4), a transcription factor important for self-
renewal of undifferentiated embryonic cells; 
- Krüppel-like factor 4 (KLF4), a repressor of p53, which is essential for the 
regulation of cell cycle; 
- SRY (sex determining region Y)-box 2 (SOX2), another transcription factor 
important for the self-renewal of undifferentiated cells; 
- Myelocytomatosis oncogene (c-MYC), a proto-oncogene crucial to drive cell 
proliferation and allow the self-renewal of ESC. 
Transduction of murine fibroblasts with retroviral vectors containing the genes 
encoding for these 4 factors resulted in the formation of colonies of cells with the same 
morphology (Figure 2), proliferation rate (Figure 3) and gene expression profile 
(Figure 4) of ESC; these cells were called "induced pluripotent stem cells" (iPSC). 
Figure 2. Morphology of an ES cell line, a colony of murine iPSC and a murine fetal fibroblasts cell line. 
Scale bar = 200µm. Takahashi, 2006. 
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Figure 3. Growth curves of ESC, iPSC                            Figure 4. RT-PCR analysis of ES cell marker 
(iPS-MEF24, clones 2-1–4), and MEFs.                           genes in iPSC (iPS-MEF24, clones 1-5, 1-9, 
3 × 105 cells were passaged every 3 days into                 and 1-18), ES cells, and MEFs. Nat1 was used 
each well of six-well plates. Takahashi, 2006.                 as a loading control. Takahashi, 2006. 
The iPSC lines produced are in fact, as ESC, formed by cells with a rounded shape, 
large nuclei and scant cytoplasm. They also showed a high proliferative rate, in fact the 
doubling time of these cells (17-19 hours) was equivalent to that of ESC (17 hours). 
Also the gene expression analysis showed the similarity of iPSC cells to ESC, as they 
express genes as Oct3/4, Nanog, E-Ras, Crypto, DAX1, Zfp196 and Fgf4, which are 
characteristic markers of undifferentiated cells. 
It was also evaluated the pluripotency of the iPSC lines produced through two different 
types of studies: 
- First, it was assessed the ability of these cells to form teratomas into 
immunodeficient animals by subcutaneous injection of cells; histological 
examination revealed that the iPSC lines generated were able, even after 
numerous passages in vitro, to give rise to tumors composed of cells derived 
from all three embryonic germ layers (Figure 5); 
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Figure 5. Histology of different tissues present in teratomas derived from the transplantation of iPSC in 
mice. Takahashi, 2006. 
- It was also evaluated the ability of these cells to differentiate in vitro into cells 
of the three embryonic germ layers. First, the formation of three-dimensional 
structures called "embryoid bodies" (EBs), a critical step to examine the 
potential of differentiation of ESC, was induced and then these clusters were 
grown in suspension condition to allow spontaneous differentiation. After a few 
days of culture, cells stained positive for the ?-smooth muscle actin (mesoderm 
marker), the ?-fetoprotein (endodermal tissues marker) and ?III tubulin 
(ectoderm marker) (Figura 6). (Takahashi & Yamanaka, 2006). 
Figure 6. Immunostaining confirming in vitro differentiation into cells of all three germ layers. Scale bars 
= 100 ?m. Secondary antibodies were labeled with Cy3 (red), except for ?-fetoprotein in iPS-MEF10-6, 
labeled with Alexa 488 (green). Scale bar = 100µm. Takahashi, 2006. 
One year later, Yamanaka’s and two other groups have successfully repeated the 
reprogramming process using human somatic cells (Takahashi et al., 2007; Yu et al., 
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2007; Park et al., 2008). Even these lines of human iPSC generated resulted comparable 
to ESC, as these cells showed the same morphology, the same proliferative capacity, 
had similar telomerase activity, a normal karyotype, expressed surface markers and 
genes that characterize human ESC, and were also able to form teratomas in vivo and to 
differentiate into cells of all three germ layers in vitro. The protocol described by 
Yamanaka’s group for the generation of iPSC by using adult human fibroblasts requires 
a first step of infection with retroviral vectors containing the genes encoding for the 4 
factors (Oct4, Klf4, Sox2 and C-Myc) and the growth in a medium containing 10% FBS 
(fetal bovine serum). After 6 days, cells are harvested using trypsin and plated on a 
layer of feeder cells (usually MEFs) inactivated with mitomycin C; from the next day 
onwards the cells are grown in the medium typically used for the culture of ESC 
supplemented with bFGF (basic fibroblast growth factor) to avoid spontaneous 
differentiation. Approximately 2-3 weeks after, flat and uniform colonies of cells 
similar to ESC start to appear with an overall efficiency of the reprogramming process 
of 0,2%; these colonies are then selected and expanded in vitro (Takahashi et al., 2007). 
Is also important to mention that Oct4, Sox2, Klf4 and C-Myc are not the only factor 
combination that can generate iPSC. For example, human iPSC have been derived by 
enforced expression of Oct4, Sox2, Nanog and Lin28 (Yu et al., 2007), suggesting that 
different routes may lead to a common pluripotent ground state or, alternatively, that 
different transcription factors activate the same program by reinforcing each other’s 
synthesis. Similarly, Sox2 and Klf4 have been replaced with related protein such as 
Sox1, Sox3 and Klf2 (Nakagawa et al., 2008). After the publication of these 
groundbreaking works, iPSC were created by reprogramming of somatic cells of 
different species, including human, mouse, rat, pig, horse and monkey (Stadtfeld & 
Hochedlinger, 2010; Kumar et al., 2015), demonstrating that the fundamental features 
of the transcriptional network governing pluripotency remain conserved during 
evolution. Similarly, iPSC have been derived from other somatic cell populations 
(Figure 7), such as keratinocytes, neural cells, stomach and liver cells, melanocytes, 
terminally differentiated lymphocytes (Singh et al., 2015) and also from pancreatic ?
cells (Stadtfeld et al., 2008), further underscoring the universality of the reprogramming 
process. 
25 
Figure 7. Different cell sources and different combinations of reprogramming factors have been used by 
different groups for reprogramming to iPSCs (O- Oct4; S- Sox2; K- Klf4; M- c-Myc; N- Nanog, L- 
Lin28). Singh, 2015.  
Studies of this type have raised an important issue, that is the need to verify whether if 
iPSC generated from different cell types are biologically and functionally similar. In 
some studies substantial differences in the propensity to form tumors in vivo or in the 
persistence of gene expression characteristic of the cell of origin were observed between 
iPSC derived from different types of somatic cells (Ben-David & Benvenisty, 2011). In 
2010 Hochedlinger’s group compared gene expression level, epigenetic profile and 
differentiation abilities of four lines of iPSC derived from different types of somatic 
murine cells; they observed that iPSC reprogrammed from cells of different nature have 
a different transcriptional and epigenetic pattern, which allows to differentiate in the cell 
type of origin with more efficiency than in other cell types. They suggest that early-
passage iPSC retain a transient epigenetic memory of their somatic cells of origin, but 
that continue passaging of the cells largely attenuates these differences and that the cell 
lines become almost indistinguishable from each other after about ten splits (Polo et al., 
2010). It should therefore to be taken into account that the somatic cells used for 
reprogramming are crucial, at least in the first steps, for the differentiation abilities of 
iPSC, since they still retain a epigenetic memory. Theoretically, to obtain iPSC 
differentiation with high efficiency, it would be more appropriate to reprogram cells at 
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least derived from the same germ layer and begin the differentiation process within a 
few passage from the reprogramming process. This strategy, however, holds issues that 
should not be underestimated, as in a recent work Batada and his group studied the 
number of CNVs (Copy Number Variations, genomic alterations in the number of 
copies of one or more regions of DNA) which are generated during the reprogramming 
process by comparing them to ESC and fibroblasts used for the production of these 
iPSC lines. They demonstrated that the median number of de novo CNVs that are 
generated from the reprogramming process are almost twice compared to ESC or 
fibroblasts, and that this number is not affected either by the presence or absence of C-
Myc or by the reprogramming strategy. The interesting element, however, is that the 
number of these CNVs decreases drastically, reaching levels comparable to ESC, during 
the passages of the cell lines, indicating that the most aberrant cells are eliminated by 
natural selection (Hussein et al., 2011). In conclusion, iPSC immediately after 
reprogramming can be differentiated with more efficiency because of their epigenetic 
and transcriptional memory, but are more genetically unstable, and consequently less 
safe. 
4.2 Safety issues 
The main problem of iPSC, which currently still preclude their use in humans is related 
to their intrinsic characteristic: as pluripotent cells, like ESC, also iPSC determine the 
formation of tumors when transplanted into immunodeficient animals. In addition, other 
problems caused by the reprogramming process itself, as the use for transfection of 
integrating virus like retroviruses, may cause insertional mutagenesis, interfere with 
gene transcription and induce tumors formation. Yamanaka and colleagues in fact 
demonstrated that after pluripotency establishment, the transgenes derived from 
retrovirus are silenced, but that each iPSC clone contained from three to six retroviral 
integrations for each factors, which may increase the risk of tumorigenesis (Takahashi 
et al., 2007). Another issue is related to the use of C-Myc, a well-known proto-
oncogene, as reprogramming factor, because it can lead to the generation of neoplastic 
formations. To overcome these obstacles, various strategies have been developed: 
- First, it was decided to eliminate the oncogene C-Myc from the set of genes 
required for reprogramming. It was in fact demonstrated that one of the causes of 
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tumor development was due to the reactivation of the C-Myc retrovirus (Okita et 
al., 2007). The same group of Yamanaka was able to achieve this goal by changing 
their reprogramming protocol doubling the time of exposure (from 1 to 2 weeks) to 
the drugs used to select the transfected cells. With this method modification they 
obtained an absolute lower number of iPSC colonies, but the obtained colonies 
were more similar to ESC colonies in terms of morphology and gene expression 
profile, indicating that without C-Myc the reprogramming process is more specific, 
even if less efficient and slower. The C-Myc free iPSC lines generated were less 
tumorigenic as compared to cells derived from the reprogramming performed using 
all 4 factors, since none of the 26 mice chimera (generated by implanting the cells 
of interest into blastocysts which are then transplanted into the uterus of pseudo-
pregnant mothers) developed tumor at 100 days from birth (Nakagawa et al., 2008).  
- To try to further improve the safety of iPSC, several reprogramming strategies 
(summarized in Table 1) which did not include the use of retroviral vectors have 
been developed. At first were tested inducible lentiviral vectors, whose expression 
can be controlled by administration of the inert drug doxycycline, decreasing the 
risks related to the continuous transgenes expression and allowing the selection 
only of fully reprogrammed cells, since cells that are dependent on exogenous 
factors expression readily stop proliferating upon doxycycline withdrawal 
(Brambrink et al., 2008). In addition, infection of different types of somatic cells is 
more efficient with lentiviral compared to retroviral vectors, and lentiviruses can 
express polycistronic cassettes encoding all four factors simultaneously, thereby 
increasing the efficiency of reprogramming process (Carey et al., 2009). Alternative 
to integrating retro or lentiviruses, non-integrating strategies have been tested for 
reprogramming, and can be divided into three categories: 
o Those that use vectors that do not integrate into the host genome: the first 
integration-free iPSC were generated using adenoviral vectors that allow a 
transient, high-level expression of exogenous genes without integrating into the 
host genome (Okita et al., 2008; Stadtfeld et al., 2008). The adenoviral vectors 
contained Oct4, Sox2, Klf4 and C-Myc genes and were delivered repeatedly to 
maintain transgene expression for up to twelve days, resulting in the generation 
of iPSC without evidence of gene integration and demonstrating the feasibility 
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of nuclear reprogramming without permanent genetic alterations. Another non-
integrating virus is represented by the Sendai virus system; Sendai virus (SeV) 
vectors replicate in the form of negative-sense single-stranded RNA in the 
cytoplasm of infected cells, which do not go through a DNA synthesis nor 
integrate into the host genome, allowing an efficient production of iPSC and 
later on elimination of the viral vector (Fusaki et al., 2009). Also self-
replicating episomal vectors for reprogramming of somatic cells were 
described (Yu et al., 2009). After spontaneous loss of the episome by 
proliferating cells, iPSC completely free of vector and transgene sequences are 
generated, but the reprogramming efficiency in human fibroblasts is 
particularly low (about three to six iPSC colonies per 106 input cells). Also 
polycistronic minicircle DNA vectors, produced by the recombinatorial 
elimination of the bacterial backbone of the original plasmids, were used for 
the generation of virus-free iPSC (Jia et al., 2010), but with an overall 
reprogramming efficiency of ~0.005% . 
o Those that use integrating vectors that can be subsequently removed from the 
genome: reprogramming efficiency with non-integrating methods is quite low, 
therefore several laboratories have developed integration-dependent gene 
delivery vectors with incorporated, at the ends of the genes of interest, loxP 
sites that can be subsequently excised from the host genome by the transient 
expression of Cre recombinase (Kaji et al., 2009; Soldner et al., 2009). It 
remains however to be assessed whether short vector sequences, which 
inevitably remain into host cell DNA after excision, affect cellular function. 
The recent development of hyperactive transposase enzymes makes transposon 
systems an interesting alternative to viral based methods, especially because 
they are able to carry large DNA cargo into cells. Transposons are mobile 
genetic elements that can be introduced and removed into host genome by 
transient expression of the transposase (Woltjen et al., 2009; Yusa et al., 2009). 
The commonly employed piggyBac and Sleeping Beauty (Kues et al., 2013; 
Talluri et al., 2014) transposon systems hold a low error rate due to a seamless 
excision, but require characterization of integration sites in iPSC before and 
after reprogramming.  
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o Those that do not use nucleic acid-based vectors: successful reprogramming 
has been achieved also without the use of viral or plasmid vectors at all. At 
first, delivery of the reprogramming factors as proteins seemed an obvious 
alternative. In 2009 transgene-free iPSC were produced with repeated 
supplementations of recombinant proteins of reprogramming factors, but with a 
low reprogramming efficiencies and a high costs for repeated treatments with 
protein factors (Zhou et al., 2009). Another group proposed the use of small 
molecules instead of transcription factors (Ichida et al., 2009): in this study 
Sox2 transcription factor was substituted by a small molecule that inhibits 
transforming growth factor-beta (TGF?) signaling and this inhibition promotes 
the completion of reprogramming through induction of the transcription factor 
Nanog. The most recent trend in the field of non-viral iPSC generation is 
reprogramming by RNA molecules. Recently, modified mRNAs encoding 
Yamanaka’s reprogramming factors were employed to generate iPSC with high 
efficiency (2-4%) without compromising genomic integrity (Warren et al., 
2010). Moreover, it was shown that also microRNA (miRNA) expression is 
sufficient to induce pluripotency. Two independent groups reported iPSC 
generation by delivery of miR302/367 cluster or miR200c, miR302, and 
miR369 (Anokye-Danso et al., 2011; Miyoshi et al., 2011). These miRNA-
derived iPSC were indistinguishable from conventionally generated iPSC and 
have the advantage of avoiding transduction of proto-oncogenic transcription 
factors.  
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Table 1. Different delivery methods for transfer of reprogramming factors for iPSC generation.  
All these new strategies allowed to successfully execute the reprogramming of somatic 
cells into iPSC without integration into genomic DNA of the cell, thereby drastically 
decreasing the tumorigenicity risk without altering the pluripotency potential of the 
reprogrammed cells. 
4.3 Current hurdles in advancing personalized iPSC 
The discovery of iPSC led to many more studies in the pluripotent arena, including the 
developing of “disease-in-a-dish” models for drug-screening platforms, the generation 
of disease-specific iPSC lines to study the pathophysiology of diseases, and creating 
personalized therapies for autologous stem cell transplantation (Matsa et al., 2014). In 
fact these cells can be derived from the somatic cells of each individual and can be used 
for autologous cell replacement therapies, theoretically avoiding the administration of 
immunosuppressive drugs. Murine or human iPSC have been successfully differentiated 
into many specialized cell types like neurons (Wernig et al., 2008), hematopoietic cells 
(Raya et al., 2009) or cardiomyocytes (J. Zhang et al., 2009) and the differentiated cells 
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may also be used to study in vitro cell types that are difficult to access or with limited 
proliferative capacity. A further advantage is that iPSC can also be obtained through the 
reprogramming of somatic cells of patients suffering from various diseases, including 
T1D (Maehr et al., 2009); the use of iPSC thus could allow to (Figure 8): 
- Study in vitro the molecular and genetic causes of the disease; 
- Perform screening of molecules in order to identify new drugs for the cure of the 
disease of interest; 
- Perform autologous or allogeneic transplants of differentiated cells (if necessary 
corrected ex vivo by homologous recombination or gene therapy) to cure the 
disease. 
Figure 8. Summary outline of the potential use of iPSC. Power, 2011. 
Therefore iPSC hold a huge potential, both in terms of cell replacement therapy for the 
possible treatment of many diseases and for the creation of in vitro models for the study 
of diseases or for drugs screening. In September 2014 the first pioneering clinical trial 
using autologous iPSC for the treatment of an AMD (age-related macular degeneration) 
patient was launched by Masayo Takahashi in Japan. After the transplantation of the 
first patient with his own iPSC-derived retinal pigment epithelial cells the trial was 
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stopped in July 2015 because the iPSC of the second enrolled patient did not pass a 
genomic validation step (6 mutations that were not present in the original somatic cells 
were found). At present then, many barriers preclude the use of iPSC in the clinical 
practice and some obstacles still need to be addressed: 
- The generation of  reprogramming strategies able to generate lines of iPSC with 
high safety and efficiency, without viral integration or genomic alterations; 
- The optimization of efficient and reliable in vitro differentiation protocols into 
the target therapeutic cell of interest 
- The post-transplantation efficacy, determined by the integration, maturation, 
survival and function of implanted cells to induce a therapeutically detectable 
effect, have to be further addressed. 
- The prospective removal (for example, before transplantation) of tumorigenic 
cells would provide the highest level of safety while reducing the need for post-
transplantation surveillance. In this context, new cell markers and methods that 
allow to select fully differentiated cells alone or to eliminate pluripotent cells are 
strongly required (Lee et al., 2013).  
- Currently  the culture media for human pluripotent stem cells contain animal-
derived components that could pose a hurdle for therapeutic use in humans. 
However, most of the issues have been solved by recent technological 
innovations such as use of animal-free culture media and reagents. Hence, we 
expect that, in the near future, clinical-grade iPSCs will be generated and 
differentiated under conditions that correspond to good manufacturing practices 
(GMPs) (Neofytou et al., 2015). 
- Last but not least, nowadays the preparation of autologous iPSC from each 
patient carries a high medical cost, and reprogramming, characterization and 
subsequent differentiation of each cell line requires several months (Ohnuki & 
Takahashi, 2015), limiting the suitability of this personalized iPSC derivative 
approach. Strategies for the generation of iPSC with low costs and short times 
are therefore strongly required.  
At present therefore, the idea of generating autologous iPSC lines cells as a source of 
transplantable cells, is not feasible in practical and economic terms for all the millions 
of patients who would benefit from this type of approach. The overall feasibility of the 
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iPSC-based therapeutic approach will be determined essentially by whether the 
technical, financial and temporal issues can be adequately resolved. With the extensive 
amount of research currently being conducted in the iPSC field, it is plausible to 
consider that these feasibility issues will be adequately addressed in due course (Byrne, 
2013). Meanwhile, many groups are working on the possibility of using allogeneic HLA 
(Human Leucocyte Antigen)-matched iPSC lines for transplantation purpose. 
Experience with solid organ and bone marrow transplantation has been used to help 
estimating the scale of iPSC banking that would be required to provide adequately 
matched tissues in a population; a study conducted on Japanese population estimate that 
50 homozygous iPSC lines would provide a haplotype match for 90.7% of individuals 
(Nakatsuji et al., 2008). These findings were confirmed in a subsequent study, which 
showed that 150 homozygous cell lines could provide a haplotype match for 93% of the 
population of the United Kingdom (Taylor et al., 2012). The generation of these iPSC 
lines would potentially be useful for the transplantation of a large number of patients, 
greatly reducing the need for immunosuppressive drugs. Another group has instead 
shown that generating a master cell bank for more diverse populations would be far 
more challenging using a probabilistic model to estimate the rate of haplotype matching 
of a carefully selected homozygous HLA-type iPSC bank for a North American 
population. According to their estimates a bank comprising 100 iPSC lines with the 
most frequent HLA in each population would leave out only 22% of the European 
Americans, but 37% of the Asians, 48% of the Hispanics, and 55% of the African 
Americans, indicating that an allogeneic cell bank in genetically homogenous countries 
like Japan or Iceland could be a viable option, but a similar bank in US would require a 
large-scale concerted worldwide collaboration (Gourraud et al., 2012). Finally, it should 
be noted that even highly matched cells could still trigger rejection. Although 
substantial debate exists within this field (Zhao et al., 2011), the current evidence 
supports the hypothesis that autologous iPSC-derived grafts are not strongly 
immunogenic. Recent studies using syngeneic mouse models demonstrated that 
transplanted iPSC-derived embryoid bodies, skin and bone marrow tissues engrafted 
efficiently with almost no signs of rejection (Araki et al., 2013; Guha et al., 2013). 
However, it would still be very difficult to predict problems with human iPSC based on 
mouse-to-mouse studies and also these problems must be addressed as soon as possible, 
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as medical communities are starting to build tissue banks that could offer 
groundbreaking treatments (Neofytou et al., 2015). 
4.4 Potential of iPSC in T1D 
Recent successes in differentiating ESC into insulin-producing cells, in combination 
with the discovery that pluripotent cells can be obtained through somatic cells 
reprograming, have raised the possibility that a sufficient amount of patient-specific ?
cells might be derived from patients through cell reprogramming and differentiation. At 
present several scientific works reported successful differentiation of ESC into cells 
capable of secreting insulin and, as mentioned previously, the pioneer in this field was 
the Viacyte group. Fundamental was their contribution to the identification of the 
growth factors able to promote the differentiation of pluripotent cells into definitive 
endoderm cells (D’Amour et al., 2005). The endoderm is the germ layer that gives rise, 
as well as epithelial cells of the respiratory and digestive systems, thyroid gland, thymus 
and liver, also to the pancreas and the pancreatic ? cells of the islets of Langerhans. 
Genetic analyses in murine animal models have shown that disruption of either the 
WNT or TGF? signaling pathways prevents formation of the primitive streak, the 
mesoderm and the definitive endoderm (Conlon et al., 1994; Lowe et al., 2001). In 
addition, high expression of Nodal, a member of the TGF? superfamily, is essential for 
specification of endoderm during gastrulation in mice, while low levels lead to 
mesoderm formation (Lowe et al., 2001; Vincent et al., 2003). Although Nodal is an 
attractive candidate for inducing definitive endoderm differentiation of ESC in vitro, a 
source of highly active protein is not readily available. However, another TGF? family 
member, Activin, binds the same Nodal receptors, triggering similar intracellular 
signaling events (de Caestecker, 2004), and therefore can be used to mimic Nodal 
activity in vitro. In this study Baetge and his team were able to demonstrate that the 
addition of Activin A to the culture media in the absence of FBS leads to the 
specification of ESC into about 80% of definitive endoderm cells (SOX17, CXCR4 and 
FOXA2 positive) (D’Amour et al., 2005). One year later the same group optimized this 
protocol reducing the days of treatment with Activin A (from 5 to 3 days) and adding in 
culture also the protein Wnt3a for the first 1-2 days, increasing the efficiency of 
differentiation into definitive endoderm cells; this initial specification has proved to be 
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crucial for an efficient production of cells capable of expressing pancreatic hormones 
(D’Amour et al., 2006). The final goal was in fact to obtain insulin-secreting cells and 
to try to this aim they looked for chemokines and growth factors that could favor the 
formation of ? cells in vitro, mimicking pancreatic organogenesis which occurs during 
embryo formation; in this study they analyzed many protocols with different 
combinations of molecules, different concentration and time of administration. What 
they achieved with this kind of approach is a 5-stages protocol (Figure 9) in which the 
production of ?-like cells is obtained through the sequential specification of human ESC 
into:  
- Definitive Endoderm (DE) through the addition of Activin A and Wnt3a in the 
absence of FBS (2-4 days); 
- Primitive Gut Tube (PG) through the stimulus given by FGF 10 and KAAD-
cyclopamine (CYC), the removal of Activin A and the presence of 2% FBS (2-4 
days). The growth factor FGF10 is usually produced by mesenchymal cells and 
is important for the growth and differentiation of the pancreatic epithelium. 
Fundamental is also the contribution of CYC, an inhibitor of hedgehog 
signaling, since the inhibition of the signaling within this pathway is 
fundamental for pancreatic specification;  
- Posterior Foregut (PF) adding to the culture medium containing FGF10 and 
CYC also Retinoic Acid (2-4 days); it rapidly induces the expression of Pdx1, 
which is a transcription factor necessary for the development and maturation of 
pancreatic ? cells; 
- Pancreatic Endoderm (PE) through the addition for 2-3 days of two molecules: 
o Exendin-4: analog of GLP-1 (glucagon-like peptide-1), which by binding to 
GLP-1R receptor leads to the activation of intracellular pathways that 
increase ? cell mass and insulin gene expression; 
o DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl] -S-phenylglycine t-
butylester) an inhibitor of Notch pathway: the decrease of the signal within 
this pathway is essential to allow the expression of Neurogenin3 (Ngn3), a 
protein produced by the endocrine progenitors and necessary for the 
development of the pancreatic endocrine cells. The production of Ngn3 in 
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turn allows the expression of two important transcription factors Nkx2.2 and 
Nkx6.1, which control the differentiation into endocrine cells. 
- Hormone-expressing Endocrine cells (EN) through the administration of 
Exendin-4 and two growth factors, IGF-1 (Insulin-like growth factor 1) and 
HGF (Hepatocyte growth factor) for 3 or more days. 
Figure 9. Scheme of differentiation procedure and protein expression for some key markers of pancreatic 
differentiation. The differentiation protocol is divided into five stages and the growth factors, medium 
and range of duration for each stage are shown. This protocol orchestrates differentiation through five 
identifiable endodermal intermediates en route to production of hormone-expressing endocrine cells. 
Several markers characteristic of each cell population are listed. CYC, KAAD-cyclopamine; RA, all-trans 
retinoic acid; DAPT, ?-secretase inhibitor; Ex4, exendin-4; ES, hES cell; ME, mesendoderm; DE, 
definitive endoderm; PG, primitive gut tube; PF, posterior foregut endoderm; PE, pancreatic endoderm 
and endocrine precursor; EN, hormone-expressing endocrine cells. D’Amour, 2006.
With this 5 stages protocol that goes in vitro through the steps that determine the 
generation of pancreatic organogenesis, D'Amour and colleagues were able to obtain 
cells expressing markers typical of each stage of differentiation and, after about 15 days 
of culture, up to 7.3% of insulin-positive cells (Figure 10), even if they are not 
responsive to glucose (D’Amour et al., 2006).  
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Figure 10. As demonstrated by immunofluorescence (A) and flow cytometry analysis (B) the cells 
resulting from the differentiation of ESC are able to produce insulin. A: DAPI (blue) for nuclei staining, 
stairs bar = 100µm. D'Amour, 2006.
After the publication of this important work, many other groups have focused on the 
possibility to generate cells capable of producing insulin from ESC and numerous 
protocols of differentiation that include the use of different molecules and growth 
conditions were created. Two studies published in 2007 described protocols for the 
differentiation of ESC into insulin-producing cells in conditions of total absence of both 
serum and feeder cells and, in particular, with the growth in suspension condition after 
the specification into pancreatic progenitor cells. The total efficiency of the production 
of insulin-positive cells was about 2-8% (J. Jiang et al., 2007) or 15% (W. Jiang et al., 
2007). Jiang W et al. also transplanted the ESC-derived insulin-producing cells into 
chemically induced diabetic mice and 30% of the animals reverted the hyperglycemic 
status; however no human C-peptide was detected in the serum of the mice, even after 
glucose stimulus (W. Jiang et al., 2007). In 2009 Melton’s group performed a screening 
of 5000 molecules in order to identify which one were able to increase the efficiency of 
the differentiation of human ESC into pancreatic-derived cells capable of expressing the 
transcription factor Pdx1. With this strategy they were able to identify a molecule, (-) - 
Indolactam V (IL V), which is able to increase the percentage of Pdx1 positive cells 
and, consequently, the amount of cells differentiating into pancreatic cells. IL V, acting 
in synergy with FGF10, allows the activation of PKC (protein kinase C) signaling, that 
regulates differentiation, proliferation and cell survival. Pdx1 positive cells were 
obtained by treatment with Activin A, Wnt3a, FGF10, CYC and, finally, administration 
of IL V; the cells were further differentiated in vitro using bFGF and nicotinamide, 
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didn’t generate insulin-secreting cells with an efficiency comparable to those obtained 
by Viacyte group (Chen et al., 2009). A common element in all of these studies is the 
observation that all the ESC lines tested were able to differentiate into pancreatic ?-like 
cells, but not with the same efficiency, making necessary the optimization of the various 
differentiation protocols for each cell line (D’Amour et al., 2006; Chen et al., 2009). 
Several strategies to differentiate ESC into cells capable of producing insulin have been 
described and, after the generation of human iPSC in 2007, these differentiation 
protocols were tested also on these induced pluripotent cells. The first paper that 
reported successful differentiation of human iPSC into insulin-secreting cells dates back 
to 2008, when the group of Zhang adapted the four-step differentiation protocol 
developed for ESC from Jiang J and colleagues (J. Jiang et al., 2007) and obtained for 
the first time ?-like cells in vitro from reprogrammed human fibroblasts. Unfortunately, 
the efficiency of differentiation process was very low and the total C-peptide content 
was significantly lower compared to adult ? cells (Tateishi et al., 2008). Subsequent 
studies focused on the culture conditions in order to increase the efficiency of 
differentiation of the iPSC into insulin-secreting cells; for example in 2010 the group 
led by Yupo Ma applied a protocol which allowed the differentiation of murine ESC in 
pancreatic ? cells (Schroeder et al., 2006) to iPSC derived from adult mouse fibroblasts. 
This differentiation protocol requires three phases: the formation of EBs through the 
growth in suspension conditions, the transfer of EBs in adhesion to allow the 
spontaneous differentiation of the cells and, finally, the addition to the culture medium 
of insulin, laminin and nicotinamide, to allow pancreatic specification. With this 
differentiation protocol Alipio et al. were able to obtain from murine iPSC up to 50% of 
cells capable of secreting insulin in response to glucose stimulus and, if transplanted 
into diabetic mice, these cells were capable to restore normoglycemia (Alipio et al., 
2010). This experiment, however, was performed only on six mice and remains to be 
confirmed if the same differentiation protocol could have the same efficiency in 
differentiating human iPSC. One year later a group reported the differentiation of 
human iPSC into insulin-secreting cells responsive to glucose using another 
differentiation protocol; it requires the culture in the absence of feeder cells and the 
addition, compared to Viacyte protocol, of two molecules, IL V (as suggested by 
Melton group) (Chen et al., 2009) and GLP-1 (instead of Exendin 4). The differentiation 
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efficiency was very low, as only 1.29% of insulin positive cells were obtained, and their 
ability to secrete insulin in vivo has not been verified. This group also reported the 
observation that the different efficiency of iPSC lines to differentiate into ?-like cells 
depends not only on genetic and epigenetic characteristics of the cells used for the 
reprogramming process, as they found variations among iPSC clones derived also from 
the same tissue of origin. This suggests that probably a different number of copies of 
pluripotency genes integrated, or different levels of silencing/reactivation of these genes 
in the various clones are able to influence the differentiation capacity of iPSC (Thatava 
et al., 2011). Encouraging results have been reported by other several in vitro studies 
that used protocols mimicking the mechanism of in vivo pancreas development to guide 
the differentiation of iPSC into ?-like cells (Zhang et al., 2009; Nostro et al., 2011; 
Kunisada et al., 2012; Hua et al., 2013), but with a lower efficiency compared to ESC. 
Moreover, none of these focused on the potential of these cells to engraft and secrete 
insulin in vivo. This is of particular relevance because in vivo engraftment could 
represent a critical step in implementing pluripotent stem cells differentiation into 
insulin-producing cells, as described for ESC (Kroon et al., 2008). Insulin-producing 
cells, although with low efficiency, were also generated with iPSC derived from the 
reprogramming of fibroblasts of two diabetic patients (Maehr et al., 2009), opening the 
way not only to autologous cell replacement therapy of T1D, but also to in vitro
modeling of this disease. As mentioned previously, iPSC were also generated using 
pancreatic ? cells as somatic cells for the reprograming, both of murine (Stadtfeld et al., 
2008) and human origin (Bar-Nur et al., 2011). Ban-Nur and colleagues reprogrammed 
human pancreatic ? cells and afterwards re-differentiated them into insulin-secreting 
cells; in this study the efficiency of differentiation was higher using ? cell-derived iPSC 
compared to ESC or iPSC generated through the reprogramming of other somatic cell 
types. These observations further confirmed the theory that iPSC retain epigenetic 
memory of the somatic cell of origin even after the reprogramming process; in 
particular, it was shown that ?-cell derived iPSC have an open chromatin structure in 
the regions coding for key genes that allow the definition of ? cells, and a methylation 
pattern that differs from that of all other iPSC lines derived from other somatic cells 
(Bar-Nur et al., 2011). However this type of approach makes impracticable the 
possibility to perform a patient-specific ? cell replacement therapy, because in diabetic 
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patients the ? cells have been destroyed by autoimmune assault. In the last few months 
two important groups described for the first time that pancreatic cells derived from the 
differentiation of pluripotent stem cells (both embryonic and induced) are capable to 
revert diabetes in mice (Rezania et al., 2014; Pagliuca et al., 2014). The main difference 
between these outstanding works consist in the timing of reversion of the disease; 
Rezania et al. in fact transplanted cells that exhibit key markers of mature pancreatic 
beta cells, but that are able to secrete insulin only after a 40 days period of further 
maturation in vivo (Rezania et al., 2014). The group of Melton instead reported a 
scalable differentiation protocol that can generate millions of glucose-responsive ? cells 
that secrete insulin shortly after transplantation. This 4-5 weeks in vitro differentiation 
protocol involves a combination of sequential culture steps using factors that affect 
signaling in numerous pathways, including signaling by WNT, Activin, Hedgehog, 
TGF?, retinoic acid and ?-secretase inhibitors and leads to the generation of ~50% of C-
peptide and Nxk6.1 double positive cells from both ESC and iPSC (Figure 11)
(Pagliuca et al., 2014).  
Figure 11. Representative flow cytometry dot plots and population percentages of cells stained for C-
peptide and NKX6-1 in HUES8 (ESC line) and two lines of iPSC. AU = arbitrary units. Pagliuca, 2014.
In conclusion, iPSC offer great hope for cell replacement therapy for diabetes, but many 
efforts still need to be done in order to make both processes of reprogramming and 
differentiation safer and more efficient.  
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III. AIM OF THE PROJECT 
Currently, the only possible strategy able to restore a physiological condition of 
normoglycemia in patients with T1D is constituted by ? cell replacement therapy, in 
particular the transplantation of pancreas in toto or purified pancreatic islets. The 
shortage of organ donors and the need of a life-long immunosuppression therapy 
however, strongly limits this approach only to a small number of patients. Is therefore 
fundamental to look for an alternative, unlimited sources of cells capable of secreting 
insulin in response to glucose stimuli. Many research groups focused on the possibility 
of differentiate ESC in vitro into ?-like cells, but this type of approach, although 
successful, it is still inefficient and limited by ethical problems. The revolutionary 
discovery of the possibility to reprogram somatic cells to an embryonic-like state 
through the expression of four genes (Oct4, Sox2, Klf4 and C-Myc) made in 2006 by 
Yamanaka’s group overcame some of these obstacles and opened the way for an 
autologous stem cells-based therapy. The overall aim of this project is to try to obtain an 
unlimited source of pancreatic ? cells from human iPSC in order to overcome the lack 
of organ donors and to get closer to an autologous ? cells replacement therapy for 
diabetic patients. To this purpose in particular we plan to: 
1) Generate iPSC lines through the reprogramming of human fibroblasts.
2) Identify a protocol that allows iPSC differentiation into insulin-producing cells  
in vitro with high efficiency.
3) Use iPSC differentiation process as a tool to study pancreatic organogenesis in vitro.
4) Test the ability of iPSC-derived pancreatic cells to differentiate and secrete insulin 
in vivo in a murine model.
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IV. MATERIALS AND METHODS 
1. iPSC generation from human skin fibroblasts 
1.1 iPSC generation with retroviral vectors and characterization
The human iPSC lines used in this study are the result of a collaboration with the 
research group of Dr. Vania Broccoli (San Raffaele Scientific Institute, Stem Cells and 
Neurogenesis Unit). Human fetal fibroblasts (IMR90 cell line, ATCC, catalogue 
number CCL-186) were reprogrammed to iPSC as previously reported (Takahashi et al., 
2007) in Broccoli’s laboratory. Briefly, fibroblasts were infected  twice (once every 24 
hours) with retroviruses expressing the transcription factors OCT4, SOX2 and KLF4 
and the day after second infection cells were plated on mitotically Mitomycin 
C (Sigma-Aldrich) inactivated murine embryonic fibroblasts (MEFs) layer on Matrigel 
(BD)-coated dishes and maintained in ESC medium. Approximately after 6 weeks after 
infection iPSC colonies started to appear and were manually picked using a 
stereomicroscope (Leica). Cells were maintained at 37°C 5% CO2. Human iPSC clones 
were characterized for pluripotency (gene and protein expression analysis of markers of 
pluripotency such as alkaline phosphatase, NANOG, OCT4, SOX2, DPPA4, FGF4, 
REX1, TDGF1,  DPPA2, GDF3, hTERT). To further corroborate the pluripotency of 
reprogrammed iPSC was verify in vitro the ability to differentiate towards cells of the 
three germ layers; in details, iPSC were cultured in ESC supplemented with 20% FBS 
for up to 20 days and then tested by immunofluorescence with corresponding markers: 
Sox17 (clone 245013, R&D) for endoderm, Smooth Muscle Actin (SMA, clone 1A4 
Abcam) for mesoderm and Neuronal Class III Beta Tubulin (clone Tuj1, Covance) and 
Nestin (clone MAB353, Millipore) for ectoderm. To corroborate their pluripotency, 
1x106 iPSCs (2 clones for each reprogrammed line) were subcutaneously injected into 
immunodeficient mice (6 week old SCID female mice, Charles Rivers) to test their 
ability to generate teratomas. After 2-3 months mice displayed subcutaneous masses 
that were dissected and paraffin-embedded. An histological evaluation of the explanted 
tissue by hematoxylin and eosin staining was performed to confirm the presence of 
teratoma. Differentiation experiments were performed on two clones (number 1 and 5). 
43 
1.2 iPSC generation with non-integrating Sendai virus vectors and 
characterization
The human integration-free iPSC (SeV-iPSC) line used in this study is the result of a 
collaboration with the research group of Dr. Gianvito Martino (San Raffaele Scientific 
Institute, Neuroimmunology Unit). Human skin fibroblasts derived from an healthy 
donor dermal biopsy explant were grown to confluence and infected with viral particles 
mixture expressing the transcription factors OCT4, SOX2, KLF4 and cMYC in 
CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Invitrogen) following manufacturer’s 
instructions. On day 7 infected human fibroblasts have been seeded on MEF layer in 
human ESC medium for 6-8 weeks. When iPSCs colonies started to appear, they were 
manually picked using a stereomicroscope (Leica) and transferred in 48 multiwell plate 
matrigel ES (BD) coated and kept in culture with mTeSR1 medium (StemCell 
Technology). Cells were maintained at 37°C 5% CO2. To assess that viral genome has 
been eliminated from the culture, RT–PCR was performed on purified RNA from iPSC 
clones using recommended set of primers for Sendai Oct4, Sox2, Klf4 and cMYC  (see 
Cytotune kit guidelines). Further, SeV-iPSC clones were characterized for pluripotency 
by RT-PCR gene expression analysis using the endo pluripotency markers for NANOG, 
OCT4, SOX2. Sev-iPSC clone 5 was characterized to assess pluripotency by 
immunofluorescence using the following Antibodies: rabbit anti-Nanog (1:150, 
Abcam); mouse anti-OCT4 (1:50, Santa Cruz Biotechnology); mouse IgM anti-TRA 1-
60 (1:100, Millipore); mouse IgM anti-TRA 1-81 (1:100, Millipore); mouse anti-SSEA4 
(1:100, Millipore); mouse anti-SSEA3 (1:100, Millipore). As secondary antibody: 
AlexaFluor 488/546 conjugated goat anti-mouse IgG (1:1000); AlexaFluor 488/564 
conjugated goat anti rabbit- IgG (1:1000); AlexaFluor 647 conjugated goat anti-Rat 
IgM (1:1000). Nuclei were stained with DAPI. Imaging was performed using a Leica 
TCS SP5 confocal microscope. To corroborate the pluripotency of reprogrammed SeV-
iPSC, the ability to differentiate into cells of the three germ layers was assessed in vitro
culturing iPSC as EB and analyzed 4 days after by immunofluorescence with 
corresponding markers: Neuronal Class III Beta Tubulin (clone Tuj1, Covance) for 
ectoderm, cytokeratin 8-18 (Ck818, Clone EP17/EP30, Dako) for endoderm, Smooth 
Muscle Actin (aSMA1, clone 1A4, A2547 Sigma) for mesoderm. Further, the 
pluripotency into cells of the three germ layers was assessed also in vivo through a 
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teratoma formation assay. Tumors were removed and paraffin-embedded tissue sections 
were stained with hematoxylin and eosin to confirm the presence of teratoma. 
2. iPSC differentiation into insulin-producing cells
2.1 Differentiation protocol 1 
Human iPSCs were differentiated into insulin-producing cells following Viacyte 
differentiation protocol with slight modifications (D’Amour et al., 2006). The 
differentiation schedule consists of 6 stages with different culture conditions: (i) stage 1, 
mesendoderm (ME) formation: RPMI 1640 (Lonza) supplemented with 100 ng/ml 
Activin A and 25 ng/ml Wnt3a (R&D Systems) for 2 days; (ii) stage 2, definitive 
endoderm (DE) formation: RPMI supplemented with 0.2% FBS (Lonza) and 100 ng/ml 
Activin A for 2 days; (iii) stage 3, primitive gut tube (PG) formation: RPMI 
supplemented with 2% FBS, 50ng/ml of Fibroblast Growth Factor-10 (FGF-10, R&D 
Systems) and 0.2 ?M KAAD-cyclopamine (CYC, Calbiochem) for 2 days; (iv) stage 4, 
posterior foregut (PF) formation: DMEM (Lonza) supplemented with 1% B27 
(Invitrogen), 50 ng/ml FGF-10, 0.2 ?M CYC and 2 ?M Retinoic Acid (Sigma Aldrich) 
for 4 days, replacing with fresh medium on the second day; (v) stage 5, pancreatic 
endoderm (PE) formation: DMEM supplemented with 1% B27, 1 ?M N-[N-(3,5-
Difluorophenacetyl) L-alanyl]-S-phenylglycine t-butyl ester (DAPT, Sigma Aldrich) 
and 50 ng/ml Exendin-4 (AnaSpec) for 3 days; (vi) stage 6, hormone expressing 
endocrine cells (EN) formation: CMRL-1066 (Connaught Medical Research 
Laboratories, Mediatech) supplemented with 1% B27, 50 ng/ml Exendin-4, 50 ng/ml 
Insulin Growth Factor- 1 (IGF-1, Sigma Aldrich) and 50 ng/ml Hepatocyte Growth 
Factor (HGF, Peprotech) for 5 days, replacing with fresh medium on the second day. 
Cells were incubated at 37° C with 5% CO2 and maintained in culture in adhesion in 6-
wells plates (Costar) until stage 4 and in 6-wells Ultra Low Attachment Plates 
(Corning) in suspension condition for stage 5 and 6. The modifications introduced are: 
(i) 300 nM Indolactam V (Alexis Biochemicals) (Chen et al., 2009) was added to the 
culture during stages 4 and (ii) cells were detached with 4 mg/ml collagenase IV 
(Gibco) and re-seeded in Ultra Low Attachment Plates for suspension culture between 
stages 4 and 5. The differentiation schedule is shown in Table 2. 
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Table 2: Protocol of differentiation of hiPSC into insulin producing cells. Pellegrini, 2015.
Cells were imaged during the differentiation steps under an inverted microscope (Leica 
DMIRE2) equipped with a digital camera (Leica DC300Fx).
2.2 Differentiation protocol 2 
Human SeV-iPSC were differentiated into insulin-producing cells following Melton 
differentiation protocol with some modifications (Pagliuca et al., 2014). The 
differentiation schedule consists of 5 stages with different culture conditions:  
- Stage 1, definitive endoderm (DE) formation: STEMdiff™ Definitive Endoderm 
Kit (Stemcell technologies) for 4 days;  
- Stage 2, primitive gut tube (PG) formation: from this stage on the medium 
(called Basal Medium, BM) used is MCDB131 (Gibco) supplemented with 
8mM D-Glucose, 1.23 g/L NaHCO3, 0.25 mM Vitamin C, 2% Bovine Serum 
Albumin (BSA, Sigma Aldrich), 1% Pen/Strep and 1% L-Glutamine (Lonza).  
For differentiation BM is supplemented with 50ng/ml of Keratinocyte Growth 
Factor (KGF, Peprotech) and 1:50000 Insulin-Transferrin-Selenium (ITS, 
Gibco) for 3 days;  
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- Stage 3, posterior foregut (PF) formation: BM supplemented with 50 ng/ml 
KGF, 0.25?M SANT1, 2?M Retinoic Acid, 200nM LDN193189 (only the first 
day) (Sigma Aldrich), 500nM Phorbol 12,13-dibutyrate (PdBU, Millipore), 
1:200 ITS for 2 days;  
- Stage 4, pancreatic endoderm (PE) formation: BM supplemented with 50 ng/ml 
KGF, 0.25?M SANT1, 100nM Retinoic Acid and 1:200 ITS for 4 days; 
- Stage 5, hormone expressing endocrine cells (EN) formation: MB supplemented 
with 12mM D-Glucose, 0,52 g/L NaHCO3, 10µg/ml Heparin (Sigma Aldrich), 
0.25?M SANT1, 100nM Retinoic Acid, , 1µM ?-secretase inhibitor XXI 
(Millipore), 10 µM Alk5 Inhibitor II (Enzo Life Science), 1µM L-3,3’,5-
Triiodothyronine (T3, Sigma Aldrich), 20 ng/ml Betacellulin (R&D) and 1:200 
ITS for 4 days. 
Cells were incubated at 37° C with 5% CO2 and maintained in culture in adhesion in 6-
wells plates (Costar) until stage 4 and in 6-wells Ultra Low Attachment Plates 
(Corning) in suspension condition for stage 4 and 5. Cells were imaged during the 
differentiation steps under an inverted microscope (Leica DMIRE2) equipped with a 
digital camera (Leica DC300Fx). 
3. Molecular analysis of iPSC differentiation 
3.1 RNA extraction and retro-transcription 
In order to assess gene expression during differentiation of iPSC, the undifferentiated 
cells and those derived from each of the 4 stages of differentiation (Figure 12) that we 
established (DE, PF, PE and EN), were washed with PBS, resuspended in 600µl of lysis 
buffer (mirVana isolation kit, Ambion) and frozen at -80° C until RNA extraction. 
Figure 12. Schematic representation of the steps of in vitro differentiation of iPSC into insulin-producing 
cells and of the 4 stages whose final products have been analyzed to verify gene expression during 
pancreatic specification. 
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Total RNA was extracted with mirVana Isolation Kit following manufacturer’s 
instructions. The quality and quantity of RNA extracted were measured by run at 100 
volts for 30 minutes on a 1.5% agarose gel and spectrophotometer lecture (Epoch 
instrument, BioTek, Gen5 analysis software). For RT-PCR, after DNAse (Invitrogen) 
treatment, RNA was retrotranscribed in a 20-µl reaction volume containing 1–5 µg of 
total RNA and SuperScript III RT, according to the manufacturer’s instructions 
(Invitrogen).  
3.2 Taqman Real-Time PCR 
PCR runs and fluorescence detection were carried out in a 7900 Real-Time PCR System 
(Applied Biosystems) at the following temperature conditions: 50° C for 2 minutes, 95° 
C for 10 minutes and 50 cycles of 95° C for 15 seconds and 60° C for 1 minute. Each 
sample was analyzed in duplicate with predesigned gene-specific primer and probe sets 
from TaqMan Gene Expression Assays (Applied Biosystems) for the following genes: 
Oct4 (Hs00742896_s1), Nanog (Hs02387400_g1), Sox17 (Hs00751752_s1), Foxa2 
(Hs00232764_m1), Hnf1b (Hs00172123_m1), Pdx1 (Ha00195591_m1), Ngn3 
(Hs00360700_g1), Nkx2.2 (Hs00159616_m1), Nkx6.1 (Hs00232355_m1), Ins 
(Hs00356618_m1), Gcg (Hs00174967_m1) and Glk (Hs00175951_m1). Normalized 
gene expression levels are reported with the highest expression set to 1 and all others 
relative to this or expressed as fold changes over glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, Hs99999905_m1) expression (2−?Ct method).  
3.3 Droplet Digital PCR (ddPCR) 
Droplet Digital PCR (ddPCR) was used to measure NANOG, SOX17, HNF1b, NGN3 
and INS absolute gene expression during differentiation. ddPCR was performed on a 
QX100 ddPCR system (Bio-Rad) using TaqMan Gene Expression Assays. A total of 
50ng of cDNA were used to set-up 3 replicate ddPCR reactions; these were emulsified 
in a QX100 droplet generator (Bio-Rad), transferred to 96 well plates and subjected to 
thermal cycling on a T100 instrument (Bio-Rad), according to the manufacturer’s 
instructions. After amplification, plates were read and individual sample droplets 
analyzed on a Bio-Rad QX100 droplet reader. The number of gene copies/ng of 
equivalent RNA was determined using the QuantaSoft v1.2.10 software, applying a 
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correction based on the Poisson distribution to the counted number of droplets positive 
for the different time points. 
3.4 MicroRNAs expression profiling and validation 
Analysis of microRNAs was performed in collaboration with the research group of Dr. 
Francesco Dotta (Diabetes Unit, Department of Medicine, Surgery and Neuroscience, 
University of Siena). MicroRNAs expression profiling was performed using Taqman 
Human MicroRNA Array Cards Panel A v2.1 + Panel B v.3.0 (Life Technologies) 
which allowed us to evaluate the expression of 768 microRNAs. MicroRNAs were 
reverse-transcribed using Megaplex Human microRNA RT primers pool A v2.1 and 
pool B v3.0 (Lifetechnologies). A total of 500ng of total RNA/each pool was used for 
reaction. Then, 9 µl of synthesized cDNA were loaded in Taqman Human MicroRNA 
Array Cards following manufacturer instructions. ViiA7 Real Time PCR instrument 
was used to perform Taqman Array Cards reaction runs.  
Real-Time PCR for single microRNA expression levels validation was performed using 
microRNA specific TaqMan MGB probe (Lifetechnologies) and TaqMan Universal 
Master Mix II in duplicate in a VIIA7 Real Time PCR instrument (Applied Biosystem) 
following manufacturer’s guidelines. The following Taqman microRNA expression 
assays were used: hsa-miR-9- ID:000583, hsa-miR-9#- ID:002231, hsa-miR-10a- 
ID:000387, hsa-miR-31- ID:002279, hsa-miR-99a- ID:000435, hsa-miR-124a- 
ID:001182, hsa-miR-127- ID:000452, hsa-miR-135a- ID:000460, hsa-miR-138- 
ID:002284, hsa-miR-143- ID:002249, hsa-miR-149- ID:002255, hsa-miR-211- 
ID:000514, hsa-miR-224- ID:002099, hsa-miR-302c#- ID:000534, hsa-miR-342-3p- 
ID:002260, hsa-miR-373- ID:000561, hsa-miR-375- ID:000564, hsa-miR-518b- 
ID:001156, hsa-miR-520c-3p- ID:002400. MicroRNA expression levels were 
normalized to the internal controls smallRNAs RNU48 and RNU6.  
3.5 Gene ontology classification analysis 
MicroRNA target genes prediction analysis was performed by Dr. Dotta’s research 
group employing the online algorithm Targetscan (Release 6.2) and applying specific 
cutoff parameters: at least 2 target sites within target gene 3’UTR sequences or, when 
just 1-site type prediction was present, a total context score <0.40. Functional 
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classification of putative microRNA target genes according to Targetscan 6.2 analysis 
was performed using DAVID (Database for Annotation, Visualization and Integrated 
Discovery) Bioinformatic Resources 6.7 as previously described (Huang, Sherman, & 
Lempicki, 2009). Briefly, predicted target genes of upregulated or downregulated 
microRNAs during differentiation stages were taken into consideration and their official 
gene name retrieved from NCBI databank (http://www.ncbi.nlm.nih.gov/gene/). Gene 
ontology classification term “Biological Process” (GOTERM_BP_ALL) was used to 
search for target genes classification categories. FDR (False Discovery Rate) corrected 
(Benjaminy-Hoechberg) p-values <0.05 were used to further select potential categories 
of interest. 
3.6 Data and statistical analysis  
For gene expression data, a nonparametric test (Mann–Whitney) was used to compare 
groups, and a 2-tailed P value less than 0.05 or 0.01 was considered significant. 
Analysis of data was performed using the SPSS statistical package for Windows (SPSS 
Inc.). For miRNA expression the data were analyzed using the Expression Suite 
Software 1.0.3 (Lifetechnologies) and GraphPad 5.1 software by applying the 2-?Ct or 
2-??Ct method and differentially expressed miRNAs were identified using a fold 
change cutoff <0.1 (downregulation) and >10.0 (upregulation). Student t-test was 
performed on normalized ?CT values in order to select significantly differentially 
expressed microRNAs (p<0.02). 
4. Cytofluorimetric analysis of iPSC differentiation 
For cytofluorimetric analysis human iPSC during the defined steps of in vitro
differentiation were dispersed into single-cell suspension by incubation in 0,25%
trypsin (BioWhittaker, CambrexBio Science) at 37°C for 5 minutes; cells were then 
collected and washed twice with PBS (Lonza). Cells were stained with Live/Dead 
(Molecular Probes, lifetechnologies) to exclude dead cells from the analysis. Intra 
cellular staining required cell fixation and permeabilization (Cytofix/Cytoperm, BD 
Bioscience). Cells were then washed with blocking buffer (PBS+2g/L Bovine Serum 
Albumin, BSA, Sigma) and stained using the following monoclonal antibodies (mAbs): 
813-70 FITC anti-Ssea-4 (BD Bioscience); 44716 PE anti-Cxcr4 (R&D); 182410 APC 
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anti-insulin (R&D); 199017 PE anti-Glut2 (R&D); CLB/TF-5 FITC anti-CD142 (Novus 
Biologicals); R11-560 PE anti-Nkx6.1 (BD Bioscience). Analysis was carried out on a 
FACS Canto flow cytometer (BD Bioscience) using FACS Diva software (BD 
Bioscience). Results were analyzed with FCS Express 4 (De Novo software) and 
expressed as the mean percentage of positive cells and standard deviation (SD) from 
multiple experiments. 
5. C-peptide content and release assays 
Human C-peptide levels in culture supernatants at every differentiation stage were 
measured using ELISA kit following manufacturer’s instructions (Mercodia). C-peptide 
release in response to stimuli was measured by incubating in vitro terminally 
differentiated iPSCs in Krebs–Ringer solution [25 mMNaCl, 5 mMKCl, 1 mM CaCl2, 
24 mM NaHCO3, 1 mM MgCl2, 10 mM HEPES, 0.1 % (wt/vol) BSA (Sigma)]. Initial 
1-h incubation was considered a wash; the medium was discarded, and this was 
followed by a 1-h incubation in basal medium containing 0.5 mM D-glucose (Sigma) 
and then a 1-h incubation in the stimulation condition [5, 11, 20 and 27 mM D-glucose 
(+ or - 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Gibco) and 30 mM KCl (Sigma)]. 
C-peptide release was then measured by C-peptide ELISA kit. The fold stimulation was 
calculated for each culture by dividing the C-peptide concentration in the stimulation 
supernatant by the C-peptide concentration in the basal supernatant. 
6. Transplantation of differentiated iPSC under the kidney capsule of 
NOD/SCID mice and evaluation of graft function 
To assess the ability of iPSC to differentiate into pancreatic cells and to secrete insulin 
in vivo, a total of 4–5 × 106 differentiated human iPSC at the stage of posterior foregut 
or of endocrine cells were transplanted under the kidney capsule of immunodeficient 
NOD/SCID mice (male, 8 weeks old, Charles River). At least 3 mice for each time 
point were transplanted. For transplantation, the animals were anesthetized by 
intraperitoneal injection of 2,2,2-Tribromoethanol (20 mg/ml, Sigma), an incision was 
made to allow the exposure of the left kidney, subsequently a small hole on the surface 
of the renal capsule was performed and the cells were infused through the use of a P-50 
catheter. Then the incision was cauterized, the kidney repositioned and subcutaneous 
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tissue and skin were sutured. Blood sugar levels were measured every week post-
transplantation with Ascensia Confirm Glucometer (Bayer). An oral glucose tolerance 
test (OGTT) was performed at 1, 4 and 12 weeks after transplantation to evaluate the 
function of the transplanted cells. OGTT was initiated after a 4-h fast; mice were given 
glucose (1 g/kg) by oral gavage. Blood samples were collected at 0, 10, 30 and 60 min 
after glucose administration and were used to determine glucose concentrations. Serum 
C-peptide was measured by ELISA assay (Ultrasensitive C-peptide ELISA kit, 
Mercodia). Care of animals was in accordance with institutional guidelines. 
7. Immunohistochemical analysis of cell engraftment and evaluation of 
graft composition  
For morphological investigations, recipient mice were sacrificed at 1, 4 and 12 weeks 
after transplantation by cervical dislocation. Kidneys were explanted and fixed in 10% 
buffered formalin (Sigma) and processed routinely for histology. Briefly, the organs 
were then embedded in paraffin and cut with microtome (Leica RM 2035). The sections 
placed on glass slides were treated with Bio-clear (Bio-Optica) for 30 minutes to 
eliminate the residual paraffin. Slides were then rehydrated with decreasing 
concentrations (from 99% to 70%) of alcohol until distilled water. The 
immunohistochemical evaluation required an initial unmasking specific for each 
antibody and subsequently the incubation of the sections with the primary antibodies 
(listed in Table 3) for 1 hour at room temperature. The peroxidase-antiperoxidase 
immunohistochemistry method (Labvision, Thermo Scientific) was used for detection. 
52 
Table 3: Antibodies used for hystochemical analysis of transplanted hiPSCs-derived cells 
The sections were counterstained with hematoxylin (Bio-Optica) and analyzed with a 
color camera, which allows scanning and digitalization of the slide by multiple vertical 
scans with 40× magnification (AperioScanscope, Leica) and acquired with the 
SpectrumTM Plus software. 
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V. RESULTS 
1. Generation and characterization of iPSC reprogrammed with 
retroviral vectors  
Human lung fetal fibroblast IMR90 cell line was infected with OCT4-, SOX2- and 
KLF4-expressing retroviruses and cultured in human ESC medium. After 6–8 weeks, 
ESC-like colonies of iPSC appeared and the clones #1 and #5 were further characterized 
and used in this study. Reprogrammed cells exhibited the typical morphology of 
pluripotent cells (Figure 13, A-B) and expressed the pluripotency-related proteins 
alkaline phosphatase (AP), OCT4 and NANOG (Figure 13, C-J).  
Figure 13. Two lines of iPSC reprogrammed from fetal fibroblasts (clones 1 and 5) were characterized in 
terms of pluripotency. A-B. Morphology of iPSC colonies at the end of the reprogramming process; C-D. 
Staining for alkaline phosphatase activity; scale bar50 µm. E-J. Staining for OCT4 (red) and NANOG 
(green) expression by immunofluorescence; nuclei evidenced by DAPI staining (blue); scale bar 25 µm. 
Molecular analysis by RT-PCR on both iPSC clones revealed the expression of the 
pluripotency related genes Oct4, Sox2, Dppa4, Fgf4, Rex1, Tdgf1, Dppa2, Gdf3 and 
hTert, that were not expressed in IMR90 fibroblasts before reprogramming (Figure 14).  
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Figure 14. Expression by RT-PCR of pluripotency genes Oct4, Sox2, Dppa4, Fgf4, Rex1, Tdgf1, Dppa2, 
Gdf3 and hTert in iPSC clone 1 and 5 and in fibroblasts before reprogramming. Beta actin was used as 
positive control gene. No-temp: negative control with no cDNA template. 
The ability of the reprogrammed cells to give rise to cells of all three embryonic germ 
layers in vitro was also tested to assess their pluripotency. After the formation of 
Embryoid Bodies (EB) and the growth on gelatine coated plates at a high percentage of 
FBS, iPSC were able to spontaneously differentiate into cells of the three germ layers, 
as shown by the expression of marker typical of endoderm (SOX17), mesoderm (SMA) 
or neuroectoderm (TUJ1 and NESTIN) cells (Figure 15).  
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Figure 15. Assessment of pluripotency in vitro. A-B: Staining for the endodermal marker SOX17 (red); 
C-D: Staining for the mesodermal marker Smooth Muscle Actin (SMA, red); scale bar 25 ?m. E-F: 
Staining for the ectodermal markers Tuj1 (green) and Nestin (red); scale bar 50 ?m. Nuclei evidenced by 
DAPI staining (blue). 
We also tested the capacity of the reprogrammed cells to give rise to all three embryonic 
germ layers in vivo through a teratoma formation assay. After injection into nude 
immunodeficient mice, both human iPSC lines were able to spontaneously differentiate 
into cells of different tissues (Figure16). 
Figure 16. Assessment of pluripotency in vivo. Staining with hematoxylin/eosin of teratomas generated 
by iPSC injected in immunodeficient mice: gut, neural and muscle-like tissues are present and indicated 
by arrows; magnification ×20. 
2. Differentiation of iPSC into insulin-producing cells in vitro
Human iPSC generated with retroviral infection of fetal fibroblasts were cultured with a 
modified version of a protocol described for the differentiation of ESC into pancreatic ?
cells (D’Amour et al., 2006). This protocol was developed after a comparative 
evaluation of the protocol described by Viacyte group with or without the 
supplementation of Indolactam V (Chen et al., 2009) and the culture in suspension 
conditions (J. Jiang et al., 2007).  
To verify the actual differentiation of human iPSC during the various stages of 
pancreatic specification (Figure 17) we evaluated the expression levels of the following 
genes: 
- OCT4 and NANOG: characteristic markers of undifferentiated cells, used to 
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assess both the real pluripotency of the iPSC used and to ensure the loss of the 
expression of these genes during differentiation; 
- SOX17 and FOXA2: characteristic markers of the definitive endoderm (DE). 
Their expression during the first steps of the differentiation determines the 
transition from pluripotent cells to DE cells; 
- HNF1b and PDX1: typical markers of posterior foregut (PF) cells. Their 
expression is fundamental for the regulation of the development of embryonic 
pancreas. PDX1 in particular, is a key transcription factor for the activation of 
insulin, glucokinase and glucose transporter type 2 (GLUT2) gene transcription. 
- NGN3 and NKX2.2: transcription factors typically expressed by pancreatic 
endoderm (PE) cells and that regulate ? cells function. 
- INS: characteristic marker of the pancreatic endocrine ? cells. 
Figure 17. Schematic representation of the stages of differentiation of iPSC into insulin-secreting cells, 
the 4 stages that have been analyzed and the genes examined to verify the gene expression of the cells 
during pancreatic specification at the end of each  stage. 
Gene expression levels are expressed as Fold Change (FC) compared to ?Ct of 
undifferentiated iPSC. The ?Ct of the 7 different replicates of iPSC used in this study, 
expressed as mean ± standard error, are: Oct4: 10.6 ± 0.4; Nanog: 6.7 ± 0.5; Sox17: 
10.5 ± 0.5; Foxa2: 9.1 ± 0.9; Hnf1b: 10.5 ± 0.7; Pdx1: 26.8 ± 2.1; Ngn3: 18.8 ± 1.3; 
Nkx2.2: 19.2 ± 2.1; Ins: 20,4 ± 1.4. 
When the protocol of differentiation proposed by D'Amour et al. in 2006 was tested on 
our human iPSC we obtained the following changes in gene expression compared to 
undifferentiated cells (Fold Change, FC = 1): 
- At the end of the first stage of differentiation the down-regulation of the 
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expression of pluripotency genes Oct4 and Nanog (0.06 and 0.04 FC 
respectively) and an over-expression of the definitive endoderm marker genes 
Sox17 and Foxa2 (48.8 and 12.6 FC). 
- At the end of the second stage the over-expression of mRNA characteristic of 
pancreatic progenitor cells: Hnf1b, Pdx1 and Ngn3 (134.9, 962.9 and 1772.5 
FC). 
- At the end of the in vitro differentiation process we observed no expression of 
the key markers and transcription factors of ? cells specification Pdx1, Ngn3, 
Nkx2.2 and, in particular, Insulin. 
We then decided to introduce two modifications to the last critical steps of in vitro
differentiation process in order to obtain the expression of insulin and of all the others 
pancreatic markers, in details: 
- the addition of Indolactam V after primitive gut tube (PG) specification to 
promote the differentiation into pancreatic endoderm cells (Chen et al., 2009); 
- the detachment of cells after posterior foregut (PF) specification and the seeding 
of cell clusters in suspension conditions mimicking in vitro pancreatic islet 
culture, to favour  ? cells maturation and survival (J. Jiang et al., 2007). 
Morphology, gene and protein expression of iPSC during differentiation with this 
modified version of the original Viacyte protocol were analyzed in seven independent 
experiments.  
Cell morphology changed from the adherent colonies of iPSC composed of small cells 
with scant cytoplasm, to bigger cell aggregates composed of a central cluster of cells 
surrounded by cells with elongated shapes, to cluster of cells in suspension condition, as 
shown in Figure 18.  
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Figure 18: Representative pictures of cell morphology of iPSC during the steps of pancreatic 
specification, scale bar 100 µm. 
We first evaluated the loss of pluripotency, that was confirmed by the downregulation 
of OCT4 and NANOG genes and the disappearance of the surface marker Ssea-4. The 
loss of the undifferentiated status was accompanied by the increase in the expression 
of SOX17 and FOXA2 genes (39.25 ± 15.78 and 7.94 ± 4.16 FC over undifferentiated 
iPSC) and of the chemokine receptor Cxcr4, characteristic traits of the definitive 
endoderm stage. At the subsequent step of posterior foregut specification, the 
upregulation of HNF1b and PDX1 genes was observed (97.14 ± 77.01, 596.34 ± 368.78 
FC), while at the following differentiation step into pancreatic 
endoderm, NGN3 and NKX2.2 genes appeared in the transforming cell population 
(83.46 ± 80.34 and 1.62 ± 0.9 FC). Furthermore, CD142 expression, previously 
described as a marker of endocrine progenitor cells (Kelly et al., 2011), increased in 
differentiating iPSC at this time point. Finally, at the end of the differentiation process, 
the production of INSULIN mRNA was highly increased (1567.92 ± 785.1 FC) and, 
accordingly, analysis by flow cytometry showed the presence of insulin-positive cells at 
the final step of differentiation, confirming the conversion of undifferentiated iPSC into 
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pancreatic cells following developmental stages (Figure 19 and 20).  
Figure 19. Gene expression analysis by Taqman of markers of pluripotency (OCT4 and NANOG), 
definitive endoderm (FOXA2 and SOX17), posterior foregut (HNF1b and PDX1), pancreatic endoderm 
(NGN3 and NKX2.2) and endocrine cells (INS). Normalized gene expression levels are reported with the 
highest expression set to 1 and all the others relative to this and expressed as mean + SEM of 7 
experiments. *P < 0.05; **P < 0.01 compared to undifferentiated hiPSC (Mann–Whitney test). Pellegrini, 
2015. 
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Figure 20. Protein expression analysis by flow cytometry of markers of pluripotency (Ssea 4), definitive 
endoderm (CXCR4), pancreatic endoderm (CD142) and endocrine cells (Ins). Gate delimitates positive 
events. Percentages of positive cells of a representative experiment are reported. SSC: side scatter, FITC: 
Fluorescein isothiocyanate, PE: phycoerythrin, APC: Allophycocyanin. Pellegrini, 2015. 
Absolute quantification by droplet digital PCR of NANOG, SOX17, HNF1B and 
NGN3 gene expression during differentiation corroborated these findings (Figure 21).  
Figure 21. Quantification of NANOG, SOX17, HNF1b and NGN3 mRNAs during differentiation of 
iPSCs into insulin-producing cells by droplet digital PCR. Gene expression was analyzed at the steps of 
pluripotency (iPSC), definitive endoderm (DE), posterior foregut (PF), pancreatic endoderm (PE) and 
endocrine cells (EN). PCR amplification of iPSCs cDNAs was performed in an emulsion using gene 
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specific primers and hydrolysis probes. The number of gene specific mRNA copies in each sample, 
corresponding to droplets fluorescing above background level (red line), was determined after droplets 
acquisition and counting on a QX100 instrument (Bio-Rad) and the QuantaSoft software v1.2.10 applying 
a correction algorithm based on the Poisson distribution. The number of gene specific mRNA copies per 
nanogram of total RNA in each sample of one representative experiment is shown. Pellegrini, 2015.
These data refer to differentiation of iPSC derived from the reprogramming of fetal 
fibroblasts; however, the protocol we set up resulted successful also for the 
differentiation of iPSC obtained from the reprograming of fibroblasts of an healthy 
adult subject (Figure 22). 
Figure 22. Gene expression of adult fibroblast-derived iPSC was analyzed during differentiation at the 
steps of pluripotency (iPSC), definitive endoderm (DE), posterior foregut (PF), pancreatic endoderm (PE) 
and endocrine cells (EN). Gene expression analysis by Taqman of markers of pluripotency (OCT4 and 
NANOG), definitive endoderm (FOXA2 and SOX17), posterior foregut (HNF1b and PDX1), pancreatic 
endoderm (NGN3 and NKX2.2) and endocrine cells (INS) is shown. Normalized gene expression levels 
are reported with the highest expression set to 1 and all the others relative to this. Histograms represent 
mean of n=2 experiments ± SEM. Pellegrini, 2015. 
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3. MicroRNAs expression profiles during iPSC differentiation into 
insulin-producing cells
Given the pivotal role of microRNAs in reprogramming of somatic into pluripotent 
stem cells (Miyoshi et al., 2011; Anokye-Danso et al., 2011), it is conceivable that this 
class of small RNAs may play a role also in the regulation of cell fate specification 
during iPSC differentiation into insulin-producing cells. Therefore, we evaluated 
microRNA expression profiles during the 4 main stages of endocrine pancreatic 
differentiation (iPSC, DE, PF and EN cells) in three independent experiments. Among 
768 microRNAs analyzed, 347 resulted expressed (Ct?35 in all samples of the same 
group). Firstly, we identified microRNAs specifically expressed in undifferentiated 
iPSC, as reported in the hierarchical heatmap clustering (Figure 23, left panel). Among 
highly expressed microRNAs (detailed zoom of hierarchical clustering analysis in 
Figure 23, right panel) we found those belonging to miR-17/92 cluster (miR-19b, 
miR-17, miR-20a, miR-19a) and its paralogs (miR-106a, miR-93) as well as miR-302 
cluster (miR-302a, miR-302b, miR-302c and miR-367), previously reported as 
representative microRNA families highly expressed in ESC and iPSC (Wilson et al., 
2009; Mogilyansky & Rigoutsos, 2013), thus demonstrating and confirming the 
pluripotent phenotype microRNA fingerprint. Indeed, microRNAs miR-19b and miR-
302b showed the highest expression levels in iPSC, reporting ?CT values of -1,18 and -
0.60 respectively. 
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Figure 23. Total microRNA expression profiles in undifferentiated human iPSC are reported in 
hierarchical clustering analysis in which normalized ?CT values of miRNAs are reported as scale colour 
(scale colour: blue=high expression; red=low expression) (Euclidean distance measure, correlation). Red 
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line highlighting upper part of hierarchical clustering represents most expressed miRNAs in iPSC. 
Detailed zoom of the red line highlighted hierarchical clustering is reported in the right panel. 
In order to verify whether microRNAs are differentially expressed during iPSC 
differentiation into insulin-producing cells and which may indeed play a role in the 
acquisition of endocrine pancreatic phenotype, we compared the microRNA expression 
profiles of iPSC during the steps of differentiation respect to undifferentiated cells. 
Taqman array profiling analysis revealed 19 microRNAs differentially expressed 
(p<0.05) during differentiation stages vs undifferentiated iPSC. Specifically, we 
observed 12 microRNAs upregulated (miR-9, miR-9#, miR-375 miR-10a, miR-99a#, 
miR-124a, miR-135a, miR-138, miR-149, miR-211, miR-342-3p and miR-224) and 7 
downregulated (miR-520c-3p, miR-302c#, miR-31,  miR-127, miR-143, miR-373, miR-
518b), reported in the hierarchical clustering heatmap (Figure 24). 
Figure 24. Hierarchical clustering analysis of differentially expressed miRNAs (fold change <0.1 and 
>10 and p<0.02, t-test): 19 miRNAs were found as differentially expressed (12 upregulated and 7 
downregulated) during progressive developmental stages (DE: definitive endoderm; PF, posterior foregut; 
EN, endocrine pancreatic cells) compared to undifferentiated iPSC. 3 replicates for each differentiation 
stage are reported. MicroRNAs expression levels are reported as ?CT values (scale colour: blue=high 
expression; red=low expression) (Euclidean distance measure, correlation) . 
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In order to confirm and validate the differential expression of those microRNAs 
identified through high-throughput profiling, we analyzed their expression by single 
assay RT-Real Time PCR. We initially validated those microRNAs, which showed an 
upregulation pattern during differentiation stages respect to undifferentiated cells; 
indeed, we confirmed the upregulation of all identified microRNAs except for miR-224 
(Figure 25). 
Figure 25. Differentially expressed microRNAs single assay validation through RT-Real Time PCR of 
upregulated microRNAs during differentiation stages. Values are reported as mean ± SEM of 2-?CT 
normalized using RNU6 and RNU48 of 3 independent experiments. * p<0.05, ** p<0.001. 
Subsequently, we also validated those microRNAs which resulted downregulated 
during endocrine pancreatic differentiation in the initial screening. The validation 
process confirmed the results obtained using the profiling approach; specifically, among 
downregulated microRNAs we identified miR-302c#, miR-518b and miR-520c-3p 
which showed a progressive decrease throughout the differentiation stages. Such 
microRNAs have been previously associated with pluripotent phenotype (Wilson et al., 
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2009; Razak et al., 2013) thus demonstrating the progressive loss of pluripotency during 
endocrine pancreatic differentiation (Figure 26).  
Figure 26. Differentially expressed microRNAs single assay validation through RT-Real Time PCR of 
downregulated microRNAs during differentiation stages. Values are reported as mean ± SEM of 2-?CT 
normalized using RNU6 and RNU48 of 3 independent experiments. * p<0.05, ** p<0.001. 
In order to reveal putative functional pathways/biological processes regulated by 
differentially expressed microRNAs identified during iPSC differentiation into insulin-
producing cells, we adopted a bioinformatic approach using two different online 
algorithms: Targetscan 6.2 (prediction of microRNA target genes) and DAVID 6.7 
(functional classification of target genes). Firstly, we obtained the putative/predicted 
microRNA target genes list using Targetscan6.2, by specifically focusing on those 
microRNAs significantly upregulated in the analyzed stages of differentiation compared 
to iPSC (Table 4).  
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Table 4: David6.7 Gene Ontology classification analysis of upregulated microRNA target genes 
subdivided into differentiation stages. Functional category accession ID (GO accession ID), specific 
name (GO term) number of genes included (NO. of Genes), percentage of gene respect to total genes 
included in the analysis (% of total), significance of gene-term enrichment with a modified Fisher's Exact 
Test corrected with Benjamini post-hoc test (p-value) and magnitude of enrichment (Fold enrichment) for 
each term are reported. Grey underlined terms were considered of particular interest in that specific 
differentiation stage. 
Interestingly, we detected several functional gene ontology (GO) categories specific for 
each differentiation stages. Specifically, we observed that microRNAs upregulated in 
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definitive endoderm stage are predicted to target several genes whose functional 
categories mainly belong to early stage morphogenesis function (‘cell morphogenesis’- 
GO:0000902 p=0.010,) whereas those upregulated in posterior foregut stage putatively 
regulate target genes involved in tissue and organ development (‘tissue development’- 
GO0009888 p<0.0001, ‘organ development’ – GO0048513 p<0.0001). Moreover, in the 
last stage of differentiation we detected several upregulated microRNA target genes 
whose functional categories can be ascribed to pancreas development and endocrine 
pancreatic cell functions (‘pancreas development’ – GO0031016 p=0.018, ‘exocytosis’-
GO0006887 p=0,032), thus suggesting a putative post-transcriptional control by 
microRNAs to those genes involved in the final stage of endocrine pancreatic 
differentiation. Next, we analyzed downregulated microRNAs target genes. 
MicroRNAs downregulated ate DE and PF stages (miR-302#, miR-518b, miR-520c-
3p), having the same set of differentially expressed microRNAs, putatively regulate the 
same set of target genes. In this case, targeted genes mainly belong to kinase control 
function (‘regulation of phosphorylation’- GO0042325 p=0,0012), whereas genes 
predicted to be targeted by downregulated microRNAs in the final differentiation stage 
mainly belong to the control of metabolic processes (‘regulation of cellular metabolic 
processes’- GO031323 p=0,0007) (Table 5). 
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Table 5: David 6.7 Gene Ontology classification analysis of downregulated microRNA target genes 
subdivided into differentiation stages. Functional category accession ID (GO accession ID), specific 
name (GO term) number of genes included (No. of Genes), percentage of genes respect to total genes 
included in the analysis (% of total), significance of gene-term enrichment with a modified Fisher's Exact 
Test corrected with Benjamini post-hoc test (p-value) and magnitude of enrichment (Fold enrichment) for 
each term are reported. Grey underlined terms were considered of utmost interest in that specific 
differentiation stage. 
4. Terminally differentiated cells exhibit ? cell characteristics 
Human iPSC terminally differentiated into pancreatic endocrine cells exhibited 
characteristics of islet cells in terms of morphology, expression and function. Cells 
clustered in structure of 50-300 microns of diameter resembling pancreatic islets, some 
with a necrotic core (Figure 27).  
Figure 27. Cell cluster morphology, scale bar 100 µm. Pellegrini, 2015. 
Endocrine commitment was confirmed by the increase of the absolute expression during 
differentiation measured through Droplet Digital PCR analysis of insulin mRNA, from 
1.1 to 13.4 mRNA copies per ng of total RNA (Figure 28).  
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Figure 28. Quantification by droplet digital PCR of Insulin mRNAs at the steps of pluripotency (iPSC), 
definitive endoderm (DE), posterior foregut (PF), pancreatic endoderm (PE) and endocrine cells (EN). 
The number of gene specific mRNA copies per nanogram of total RNA in each sample, corresponding to 
droplets fluorescing above background level (red line), was determined after droplets acquisition, count 
on a QX100 instrument (Bio-Rad) and analysis by QuantaSoft software v1.2.10. Pellegrini, 2015. 
Cytofluorimetric analysis confirmed the presence of insulin positive cells, in a range 
between 1.8 and 6.7%. At the final step of differentiation, iPSC-derived cells resulted 
positive for glucose transporter 2 (Glut2) (Figure 29).  
Figure 29. Protein expression analysis by flow cytometry of glucose transporter 2 (Glut2). Gate 
delimitates positive events. Percentage of positive cells of a representative experiment is reported. SSC: 
side scatter, PE: phycoerythrin. Pellegrini, 2015. 
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Moreover, the expression of the glucokinase gene, a critical enzyme involved in the 
glucose responsiveness of insulin release emerged in terminally differentiated cells 
(Figure 30).  
Figure 30. Expression analysis by Taqman of Glucokinase mRNA during the differentiation steps (iPSC, 
DE, PF, EN). Expression levels are reported as fold change compared to undifferentiated cells. Pellegrini, 
2015. 
Furthermore, at the end of the differentiation process, iPSC-derived cells secreted 
insulin in resting conditions, as shown by the presence of c-peptide in culture 
supernatants (Figure 31). 
Figure 31. C-peptide level in the supernatant of iPSC during the differentiation steps (iPSC, DE, PF, EN) 
measured by Elisa. Graph reports single values of 5 experiments as dots and mean±SEM. Pellegrini, 
2015. 
When insulin secretion was tested in stimulated conditions, a range of concentrations of 
glucose per se was not sufficient to increase insulin release, while the combination of 
glucose with phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) induced 
a significant release of insulin; stimulation of insulin release was also obtained by direct 
depolarization with potassium chloride (KCl) (Figure 32). 
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Figure 32. C-peptide secretion by terminally differentiated iPSC upon stimulation with 0,5, 5, 11, 20 and 
27 mM glucose without or with 0,5 mM IBMX and KCl, measured by Elisa and reported as ratio between 
stimulated and basal condition. Data are shown as mean + SD of 3 experiments. *P < 0.05; **P < 0.01 
compared to 0.5 mM glucose stimulus (Mann–Whitney test). Pellegrini, 2015. 
5. iPSC-derived cells engraft and survive for short-term periods when 
transplanted in vivo 
To test the capability to engraft, to survive and to release insulin in vivo, we 
transplanted terminally differentiated human iPSC under the kidney capsule of 12 
immunodeficient normoglycemic NOD/SCID mice. Fasting glycemia was measured in 
recipient mice during 12-week follow-up. Mice remained normoglycemic during the 
follow-up. One week after transplantation, grafts were responsive to glucose since 
human C-peptide was detected in the sera after an oral glucose tolerance test, but grafts 
gradually lost insulin production during the time (Figure 33).  
Figure 33. Functional characterization of iPSC-derived cells after transplantation in NOD/SCID mice. 
Analysis of graft function by human C-peptide measurement after oral glucose test tolerance in sera of 
mice transplanted with iPSC-derived-terminally differentiated cells. Pellegrini, 2015.
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Since terminal differentiation of pluripotent stem cells into pancreatic hormone-
secreting cells was described to occur efficiently in vivo (Kroon et al., 2008), we also 
transplanted iPSC-derived pancreatic endoderm cells. One week after transplantation, 
mice had significant basal levels of circulating C-peptide, but they were not responsive 
to glucose stimulation. Four weeks after transplantation, they acquired the ability to 
respond to glucose with an increase in insulin production, but, as observed for 
terminally differentiated iPSC transplant, transplanted cells were shown to gradually 
lose insulin production during the time, from the first week onwards (Figure 34). 
Figure 34. Functional characterization of iPSC-derived cells after transplantation in NOD/SCID mice. 
Analysis of graft function by human C-peptide measurement after oral glucose test tolerance in sera of 
mice transplanted with iPSC-derived pancreatic progenitor cells. Pellegrini, 2015.
In order to investigate engraftment, survival and localization of transplanted cells, we 
performed an immunohistochemical analysis of the graft at 1, 4 and 12 weeks after cells 
infusion. At 1 and 4 weeks, the grafts of mice transplanted with terminally 
differentiated cells showed the presence of proliferating cells (Ki67 positive cells) and 
pancreas-committed cells (Pdx1 positive). Significant number of insulin-positive cells 
was present only in the graft collected at the earliest time point of 1 week (Figure 35). 
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Figure 35. Immunohistochemical characterization of iPSC-derived cells after transplantation in 
NOD/SCID mice. Evaluation of grafts by immunohistochemistry 1 and 4 weeks after transplantation of 
terminally differentiated cells. Ki-67 staining was used to assess proliferation, Pdx1 and Ins as pancreatic 
markers. Scale bar 50 µm. Pellegrini, 2015.
At 12 weeks, immunohistochemical analysis of the graft showed that only few cells 
were present and resulted positive for Pdx1 and for glucagon, but not for insulin 
(Figure 36) and in 5 out of 6 mice the graft was not even visible. 
Figure 36. Immunohistochemical characterization of iPSC-derived cells after transplantation in 
NOD/SCID mice. Evaluation of grafts by immunohistochemistry 12 weeks after transplantation of 
terminally differentiated cells. Pdx1, Ins and Glucagon were used as pancreatic markers. Scale bar 50 µm.  
When the infusion of pancreatic endoderm cells was analyzed, immunohistochemical 
analysis of the grafts at all considered time points showed that transplanted cells 
engrafted, survived and did not infiltrate the surrounding tissues. The grafts resulted 
composed of a mixed population of cells containing proliferating components (Ki67 
positive), pancreatic cells (Pdx1-positive) and few scattered insulin-positive cells in the 
graft at 1 and 4 weeks after transplantation (Figure 37).  
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Figure 37. Immunohistochemical characterization of cells after transplantation in NOD/SCID mice. 
Evaluation of grafts by immunohistochemistry 1 and 4 weeks after transplantation of iPSC-derived 
pancreatic endoderm cells. Ki-67 staining was used to assess proliferation, Pdx1 and Ins as pancreatic 
markers. Scale bar 50 µm. Pellegrini, 2015.
At 12 weeks, all grafts were still retrievable, Ki67 and Pdx1 positive cells persisted in 
the graft area, while insulin-positive cells were not found (Figure 38).  
Figure 38. Immunohistochemical characterization of cells after transplantation in NOD/SCID mice. 
Evaluation of grafts by immunohistochemistry 12 weeks after transplantation of iPSC-derived pancreatic 
endoderm cells. Ki-67 staining was used to assess proliferation, Pdx1 and Ins as pancreatic markers. 
Scale bar 50 µm. 
At all time points, both after terminally differentiated or pancreatic endoderm cell 
transplantation, it was possible to find cells expressing markers of pluripotency (Sox2), 
markers of secretory cells not specifically pancreatic (ChgA, Syp), markers of epithelial 
cells (Ck8-18), pancreatic endocrine cells expressing glucagon and some neuronal 
lineage-committed cells (Gfap positive) (Figure 39). 
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Figure 39. Immunohistochemical characterization of iPSC–derived cells after transplantation in 
NOD/SCID mice. Sox2 staining was used to assess pluripotency, Synaptophysin (Syp) and 
Chromogranin A (ChgA) for secretory cells, cytokeratin 8 and 18 (Ck8/18) as epithelial cell markers, 
glial fibrillary acidic protein (Gfap) to detect any neuronal cells and Glucagon (Gcg) as a marker of 
pancreatic endocrine cells. These images are representative for graft composition at 1, 4 and 12 weeks, 
after infusion of precursors or of terminally differentiated cells. Scale bar: 100µm. Pellegrini, 2015.
6. Generation and characterization of iPSC reprogrammed with 
Sendai Virus 
Human iPSC were then generated using Sendai (Fusaki et al., 2009) non-integrative 
virus vectors containing the four Yamanaka’s factors. The clone #5 obtained from the 
reprogramming of fibroblasts derived from a skin biopsy of a healthy adult subject was 
used in this study after the assessment of its pluripotency. Reprogrammed cells indeed 
stained positive for the pluripotency-related proteins Oct4, Nanog, Tra1-60, Tra 1-81, 
SSEA4 and SSEA4 (Figure 40).  
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Figure 40. One line of iPSC reprogrammed from adult fibroblasts (clone 5) was characterized in terms of 
pluripotency. Staining for expression by immunofluorescence: A-C: OCT4 (red) and NANOG (green); D: 
Tra1-60 (red); E: Tra1-81 (red); F: SSEA4 (red) and SSEA3 (green); nuclei evidenced by DAPI staining 
(blue). Magnification ×10. 
Also at molecular level Sendai virus (SeV)-iPSC expressed, as the iPSC generated with 
retroviral infection, all the marker genes of pluripotency like OCT4, KLF4, SOX2 and 
NANOG, while the uninfected fibroblasts expressed only low levels of KLF4. Analysis 
of fibroblasts immediately after infection with SeV revealed the expression of Sendai 
Virus mRNA, that was lost after pluripotency establishment (Figure 41).  
Figure 41. Expression by RT-PCR of pluripotency genes OCT4, KLF4, SOX2 and NANOG and of SeV 
in iPSC clone 5, iPSC generated with retroviral infection, in fibroblasts before reprogramming and 
fibroblasts after SeV infection. Negative control: no cDNA template. 
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The ability of the reprogrammed cells to give rise to cells of all three embryonic germ 
layers in vitro was also tested. After EB formation SeV-iPSC were differentiated into 
cells of the three germ layers, as shown by the expression of marker typical of ectoderm 
(bIII Tubulin), endoderm (Cytokeratin 18) and mesoderm (aSMA) (Figure 42).  
Figure 42. Assessment of pluripotency in vitro. A: Staining for the ectodermal markers bIIITubulin 
(green). B Staining for the endodermal marker Ck18 (green); C: Staining for the mesodermal marker 
aSMA (green). Nuclei evidenced by DAPI staining (blue). Magnification 10x. 
Also the capacity of SeV-iPSC to form teratoma in vivo was tested. After injection into 
nude immunodeficient mice reprogrammed cells were able to spontaneously 
differentiate into cells of different tissues (Figure 43). 
Figure 43. Assessment of pluripotency in vivo. Staining with hematoxylin/eosin of teratomas generated 
by SeV-iPSC injection into immunodeficient mice: gut, neural and muscle-like tissues are present. 
magnification ×20. 
7. Differentiation of SeV-iPSC into insulin-producing cells in vitro
7.1 Differentiation protocol 1 
The protocol previously described for the differentiation of iPSC generated with 
retrovirus was tested also on SeV-iPSC. Morphology, gene and protein expression of 
SeV-iPSC during differentiation were analyzed in four independent experiments.  
Cell morphology changed from the adherent colonies of iPSC composed of small cells 
with scant cytoplasm, to stellate cells, to cluster of cells in suspension condition, as 
shown in Figure 44. 
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Figure 44. Representative pictures of cell morphology of SeV-iPSC during the steps of pancreatic 
specification, Magnification 10x. 
Gene expression levels are expressed as Fold Change (FC) compared to ?Ct of 
undifferentiated SeV-iPSC. The ?Ct of 12 different replicates of iPSC used in this 
study, expressed as mean ± standard error, are: Oct4: 9.44 ± 0.1; Nanog: 5.9 ± 0.1; 
Sox17: 18.3 ± 0.9; Foxa2: 13.3 ± 0.2; Hnf1b: 18.1 ± 0.4; Pdx1: 28.1 ± 1.6; Nkx2.2: 18.7 
± 0.1; Nkx6.1: 16.9 ± 0.2; Ins: 30,1 ± 1.1; Gcg: 30.7 ± 0.1. 
We first evaluated the loss of pluripotency, that was confirmed by the downregulation 
of OCT4 and NANOG genes, and the loss of the undifferentiated status was 
accompanied by the increase in the expression of SOX17 and FOXA2 genes (8096.7 ± 
1681.4 and 973.4 ± 190.8 FC over undifferentiated iPSC) during specification into 
definitive endoderm cells (Figure 45).  
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Figure 45. Gene expression analysis by Taqman of markers of pluripotency (OCT4 and NANOG) and 
definitive endoderm (FOXA2 and SOX17) during the stages of pancreatic differentiation. Normalized 
gene expression levels are reported as fold change compared to undifferentiated SeV-iPSC and expressed 
as mean ± SEM of 4 experiments. 
At the step of posterior foregut specification, the upregulation of HNF1b and PDX1 
genes (11086.5 ± 1514.9, 47811.5 ± 20399.5 FC) and their sustained expression during 
the subsequent steps of differentiation was observed (Figure 46). 
Figure 46. Gene expression analysis by Taqman of markers posterior foregut (HNF1b and PDX1) during 
the stages of pancreatic differentiation. Normalized gene expression levels are reported as fold change 
compared to undifferentiated SeV-iPSC and expressed as mean ± SEM of 4 experiments. 
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At the final differentiation step the overexpression of the transcription factors NNK2.2 
and NKX6.1 (75.8 ± 32.1 and 7.3 ± 3.1 FC) and of the mRNA of the pancreatic 
hormones Insulin and Glucagon (420976.6 ± 292501.4 and 125333.7 ± 81977.4 FC)  
were observed (Figure 47). 
Figure 47. Gene expression analysis by Taqman of markers pancreatic endoderm (NKX2.2 and NKX6.1) 
and endocrine cells (INS and GCG) during the stages of pancreatic differentiation. Normalized gene 
expression levels are reported as fold change compared to undifferentiated SeV-iPSC and expressed as 
mean ± SEM of 4 experiments. 
Accordingly, analysis by flow cytometry showed the disappearance of the pluripotency 
surface marker Ssea-4 (from 98% to 7% of positive cells) during differentiation steps, 
the increase of Cxcr4 positive cells at the stage of definitive endoderm (from 0,17% of 
iPSC to 89,44% after DE specification), and presence of few insulin (0,59%), Glut2 
(0,86%) and double-positive (0,36%) cells at the final step of differentiation, confirming 
the conversion of undifferentiated iPSC into pancreatic cells following developmental 
stages although with low efficiency (Figure 48).  
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Figure 48. Protein expression analysis by flow cytometry of markers of pluripotency (Ssea 4), definitive 
endoderm (CXCR4) and endocrine cells (double staining for GLUT2 and Insulin). Gate delimitates 
positive events. Percentages of positive cells of one experiment are reported. SSC: side scatter.
7.2 Differentiation protocol 2 
We optimized a new differentiation protocol for our SeV-iPSC relying on the protocol 
described by Melton’s group for the pancreatic differentiation of pluripotent cells 
(Pagliuca et al., 2014). Compared to their protocol we added some modifications: 
- we used the STEMdiff™ Definitive Endoderm Kit for the differentiation into 
definitive endoderm cells a commercial medium able to give rise to DE cells 
from pluripotent cells. 
- we have grown iPSC in adhesion condition until the specification into posterior 
foregut cells as previously described. 
Before the introduction of these two modification we observed a gradual and 
progressive death of the cells during the last step of the differentiation process and it 
was not possible to perform gene or protein expression analysis. 
Morphology, gene and protein expression of SeV-iPSC during differentiation with this 
new modified protocol were analyzed in 2 independent experiments.  
83 
Cell morphology changed from the adherent colonies of iPSC composed of small cells 
with scant cytoplasm, to bigger cell aggregates composed of a central cluster of cells 
surrounded by cells with elongated shapes, to cluster of cells in suspension condition, as 
shown in Figure 49. 
Figure 49. Representative pictures of cell morphology of SeV-iPSC during the steps of pancreatic 
specification, Magnification 10x. 
Also with this protocol we observed the loss of pluripotency (downregulation of OCT4 
and NANOG genes) and the increase in the expression of SOX17 and FOXA2 genes 
(7547.7 ± 3655.5 and 1159 ± 899.1 FC over undifferentiated iPSC) during specification 
into definitive endoderm cells (Figure 50). 
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Figure 50. Gene expression analysis by Taqman of markers of pluripotency (OCT4 and NANOG) and 
definitive endoderm (FOXA2 and SOX17) during the stages of pancreatic differentiation. Normalized 
gene expression levels are reported as fold change compared to undifferentiated SeV-iPSC and expressed 
as mean ± SEM of 2 experiments. 
At the step of posterior foregut specification, the upregulation of HNF1b and PDX1 
genes (27282.8 ± 830.9, 1797153.7 ± 225679.6 FC) and their sustained expression 
during the subsequent steps of differentiation was observed (Figure 51). 
Figure 51. Gene expression analysis by Taqman of markers posterior foregut (HNF1b and PDX1) during 
the stages of pancreatic differentiation. Normalized gene expression levels are reported as fold change 
compared to undifferentiated SeV-iPSC and expressed as mean ± SEM of 2 experiments. 
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At the final differentiation step the overexpression of the transcription factors NNK2.2 
and NKX6.1 (3653 ± 453.7 and 477.4 ± 47.3 FC) and of the mRNA of the pancreatic 
hormone Insulin and Glucagon (12319377.1 ± 6234648.6 and 2905349 ± 1504064.4 
FC)  were observed (Figure 52). 
Figure 52. Gene expression analysis by Taqman of markers pancreatic endoderm (NKX2.2 and NKX6.1) 
and endocrine cells (INS and GCG) during the stages of pancreatic differentiation. Normalized gene 
expression levels are reported as fold change compared to undifferentiated SeV-iPSC and expressed as 
mean ± SEM of 2 experiments. 
Finally, analysis by flow cytometry of cells differentiated in vitro until the last stage 
confirmed the presence of insulin (14.23%) and Nkx6.1 (46.09%) positive cells (Figure 
53).  
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Figure 53. Protein expression analysis by flow cytometry of Insulin and Nkx6.1. Gate delimitates 
positive events. Percentage of positive cells of one experiment is reported. SSC: side scatter.
Insulin positive cells were detected also by immunohistochemical analysis performed 
on the cytospinned terminally differentiated cells (Figure 54). 
Figure 54. Immunohistochemical characterization of Sev-iPSC-derived pancreatic endocrine cells 
differentiated in vitro. Insulin was used as ? cell markers. Scale bar 100µm. 
Furthermore, at the end of the differentiation process, SeV-iPSC-derived cells secreted 
insulin in resting conditions, as shown by the presence of c-peptide in culture 
supernatants (Figure 55). 
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Figure 55. C-peptide level in the supernatant of iPSC during the differentiation steps (iPSC, DE, PF, PE, 
EN) measured by Elisa. Graph reports single values of 2 experiments as dots and mean±SEM.  
When insulin secretion was tested after glucose stimulus (in the presence of IBMX) a 
significant release of c-peptide was observed; stimulation of insulin release was also 
obtained by direct depolarization with potassium chloride (KCl) (Figure 56). 
Figure 56. C-peptide secretion by terminally differentiated SeV-iPSC upon stimulation with 0,5 (without 
or with 0.5mM IBMX) and 20 mM glucose (+0.5mM IBMX) and KCl measured by Elisa and reported as 
ratio between stimulated and basal (0.5 mM glucose) condition. 
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VI. DISCUSSION 
Many efforts in the field of diabetes research have been put on differentiating 
pluripotent stem cells to find an unlimited new source of pancreatic ? cells. The overall 
aim of this project is to try to obtain an unlimited source of insulin producing cells from 
human iPSC in order to overcome the lack of organ donors and to get closer to an 
autologous ? cells replacement therapy for diabetic patients. In this study, we reported a 
method for promoting the differentiation of iPSC into insulin-producing cells and we 
transplanted these differentiated pancreatic cells in vivo. The results obtained showed 
that human iPSC have the potential to generate functional insulin-producing cells in 
vitro, undergoing defined steps resembling pancreas organogenesis, and that 
differentiated cells can engraft and survive for short periods when transplanted in vivo. 
These data provide useful suggestions for the study of a potential use of induced 
pluripotent stem cells in the field of ? cell replacement for diabetes treatment.  
For the differentiation of our human iPSC reprogrammed with retroviral vectors 
containing the 4 Yamanaka’s factors, we selected as a backbone the most efficient 
protocol for in vitro differentiation of ESC (D’Amour et al., 2006). We added slight 
modifications to this protocol in order to obtain an efficient differentiation of iPSC into 
the pancreatic lineage. With the addiction of the PCK activator Indolactam V (Chen et 
al., 2009) and the culture in suspension condition mimicking in vitro pancreatic islet 
culture (J. Jiang et al., 2007), the highest differentiation efficiency reached with this 
iPSC cell line was approximately 7% of insulin-positive cells, measured by flow 
cytometry. Gene expression data, both by Taqman and by Digital PCR, confirmed that 
terminally differentiated cells underwent all the steps of pancreatic organogenesis, 
expressing all the keys genes and transcription factors characteristic of each stage of 
differentiation. In particular, we observed a downregulation of the pluripotency markers 
Oct4, Nanog and SSEA-4 during pancreatic differentiation, although Oct4 expression 
was detected also during the last stage of in vitro differentiation; this observation is 
consistent with a study that reported Oct4 expression in pancreatic islet of healthy 
subjects (Iki & Pour, 2006). During specification to definitive endoderm cells, we 
detected a significant upregulation of the genes Sox17 and Foxa2 and of the microRNA 
miR375 (a key regulator of pancreatic development) (Lahmy et al., 2013), and an 
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increase in the percentage of Cxcr4 positive cells, confirming the differentiation of 
iPSC into DE cells. At the subsequent step of posterior foregut specification, the 
upregulation of Hnf1b and especially of the fundamental transcription factor Pdx1 was 
observed, while at the following differentiation step into pancreatic endoderm, also the 
genes Ngn3 and Nkx2.2, essential for ? cell specification, resulted more expressed. 
Finally, at the end of the differentiation process, insulin mRNA expression resulted 
highly increased. In addition to insulin expression, other characteristics are needed to 
establish that iPSC have indeed generated functional ? cells. Here, the final cell product 
presents distinctive features of mature ? cells as the expression insulin, Glut2, 
Glucokinase, and of the microRNAs miR9 and miR-124a, two non-coding RNAs which 
have been described to play an active role in regulating insulin secretion (Baroukh & 
Van Obberghen, 2009; Ramachandran et al., 2011). Differentiated cells also showed the 
ability to secrete C-peptide in basal and stimulated conditions. Our in vitro results are in 
line and extend the few previous publications on human iPSC differentiation in ? cell 
(Tateishi et al., 2008; D. Zhang et al., 2009; Nostro et al., 2011; Thatava et al., 2011; 
Kunisada et al., 2012; Hakim et al., 2014). The differentiation of iPSC to insulin-
producing cells with a process able to mimic every stage of pancreatic organogenesis 
represents also a powerful tool for the in vitro study of pancreas development. In the 
present study, we reported the characterization of microRNAs expression profiles 
during differentiation of iPSC into insulin-producing cells in order to discover which 
microRNAs regulate ? cells specification. During in vitro differentiation we detected 
the progressive upregulation of 11 microRNAs and downregulation of 7 microRNAs. 
The concept that microRNAs operate in concert in well-defined gene networks (Herranz 
& Cohen, 2010), prompted us to analyze the functional classification of predicted target 
genes belonging to differentially expressed microRNAs grouped into ‘upregulated’ or 
‘downregulated’ in each differentiation stages respect to undifferentiated iPSC. Indeed, 
target genes analysis showed that microRNAs synergistically regulate cohorts of genes 
that participate in similar processes. Specifically, ontological analysis of microRNAs 
target genes revealed that those upregulated in DE and PF stages are predicted to 
regulate several genes whose functions can be ascribed to the control of tissue 
development or cell morphogenesis. MicroRNAs upregulated in the final stage of 
differentiation are instead predicted to target several genes involved in pancreas 
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development and exocytosis control. These data demonstrate that several microRNAs 
are upregulated during differentiation, in order to progressively control specific target 
genes involved in developmental processes or endocrine-pancreatic cell fate 
specification. For downregulated microRNAs instead, bioinformatic analysis revealed 
that most of their target genes belong to ‘regulation of phosphorylation’ (DE and PF 
stages) while ‘regulation of metabolic processes’ was the most significant category in 
the final stage. Interestingly, it has been recently reported that during differentiation of 
pluripotent stem cells, more than 50% of phospho-sites are regulated, providing 
evidence of the involvement of protein phosphorylation as a mechanism of cell fate 
specification (Van Hoof et al., 2009). In this context, the downregulation of such 
microRNAs may allow on one side the expression of those genes involved in 
phosphorylation processes and, on the other, facilitate the expression of those involved 
in metabolic processes, thus favoring the endocrine-pancreatic phenotype specification 
during differentiation. These results could therefore lead to the identification of markers 
of novel pathways and/or individual targets for possible pharmacological interventions 
able to increase the efficiency of the differentiation process. 
This is the one of the first studies in which human iPSC-derived pancreatic cells are 
transplanted in vivo in animal models. One recent paper reported C-peptide production 
after in vivo infusion of human iPSC differentiated to ? cells, but the study was mainly 
focused on the correction of glucokinase deficiency in iPSC derived from MODY 
patients (Hua et al., 2013). Other previous in vivo experiences were limited to mouse 
iPSC, showing that transplantation of differentiated cells are able to correct 
hyperglycemia in models of type 1 and 2 diabetes (Alipio et al., 2010; Jeon et al., 2012).  
Only very recently two groups reported for the first time that pancreatic cells derived 
from the differentiation of pluripotent cells (both ESC and iPSC) were able to revert 
diabetes in mice within few weeks (Rezania et al., 2014; Pagliuca et al., 2014). In our 
study, we transplanted human iPSC-derived cells both at the stage of endocrine 
(INSULIN positive cells) and of pancreatic endoderm cells (PDX1 positive cells). In the 
first case, cells engrafted and we were able to find them in the graft, although only after 
a short period of observation, while after 3 months the infused cells had almost 
completely disappeared. The graft resulted composed not only of pancreatic lineage 
cells (expressing Pdx1, insulin and glucagon), but also of pluripotent and of other 
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lineages cells. Significant number of insulin-positive cells was found only in grafts 
retrieved 1 week after infusion and not after 4 and 12 weeks. Accordingly, mice 
responded to oral glucose stimulus by releasing human C-peptide from the graft only 1 
week after transplantation. Borrowing the experience from ESC (Kroon et al., 2008), we 
also transplanted iPSC-derived pancreatic endoderm cells: precursors survived and 
engrafted, but, as for terminally differentiated cells, at the longest time of follow-up, we 
were not able to find insulin-positive cells and mice did not secrete human C-peptide. 
Also in this setting, the graft we retrieved was characterized by a mixed population of 
pancreatic, neuronal and undifferentiated cells. We hypothesize that insulin-positive 
cells may have been replaced by undifferentiated cells in proliferation or have lost their 
pancreatic commitment. Besides, also the degree of neo-vascularization of the graft may 
have influenced insulin-positive cell survival, since it is well known that islet 
vasculature provides critical instructive signals necessary for ? cell differentiation and 
survival (Reinert et al., 2013). Finally, we can speculate that the infusion of a mixed 
population of cells, reflected by a heterogeneous graft, could decrease the efficacy of 
insulin production, increase tumorigenicity and negatively impact on differentiated cell 
survival. To improve safety and avoid risk of tumorigenesis, it would be necessary to 
select only cells of pancreatic lineage. Several attempts have been made to look for new 
surface markers able to select pancreatic progenitors (Jiang et al., 2011; Kelly, Chan, L. 
A. Martinson, et al., 2011) or to get rid of unwanted pluripotent cells (Ben-David et al., 
2013), but the safety of the selected cells still requires further investigation. Besides, 
some transcriptional factors or genes such as Pdx1, Ngn3 or Insulin could be used as 
selection markers, but they have intracellular or intranuclear expression; therefore, 
standard sorting strategies cannot be applied. Very recently, however, novel methods 
for cell selection based on fluorescent nanoparticles capable of detecting mRNA targets 
inside living cells have been developed (Lahm et al., 2015). These tools would allow 
separation of cells at different stages of maturation with significant reduction of 
contaminating cells.  
To try to increase the safety of iPSC and to get closer to an eventual clinical traslation 
of this type of approach, we moved to the use of iPSC generated through infection of 
Yamanaka’s factors with Sendai virus, a RNA-based virus able to reprogram somatic 
cells with a relatively high efficiency (0,1%) avoiding transgenes integration into the 
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host genome (Fusaki et al., 2009). We first tested our in vitro differentiation protocol on 
one clone of SeV-iPSC and also with this cell line we obtained the differentiation into 
insulin-producing cells following all the steps of pancreatic organogenesis. Compared 
to retrovirus-generated iPSC, we observed a higher expression of all the the key genes 
and transcription factors characteristic of each stage of differentiation, including insulin 
(1567,9±785.1 FC compared to 420976.6±292501.4 FC over undifferentiated iPSC), 
but the total number of insulin positive cells detected was lower. These differences in 
the efficiency of differentiation are reported also in the literature, and can be ascribed to 
the variety of protocols but also to the characteristics of the pluripotent cells used, 
which are different in terms of source, reprogramming methods and culture conditions 
in every single experience. In fact, also in the ESC field, it has been published that 
different cell lines show different propensity to give rise to pancreatic cells (Osafune et 
al., 2008). We then tested a newly described differentiation protocol able to differentiate 
pluripotent cells to ?-like cells with high efficiency (Pagliuca et al., 2014) on SeV-iPSC, 
but we observed a gradual cell death during the last steps of the differentiation process. 
We then decided to add some modifications to the published protocol: the use of a 
commercial kit for a standardized and efficient differentiation into definitive endoderm 
cells and the growth in suspension conditions during the last steps of in vitro
differentiation as previously described. The protocol defined by Pagliuca et al., 
involves, compared to the protocol of the Viacyte group, the use of different molecules 
but able to affect the same pathways (KGF instead of FGF-10, the sonic hedgehog 
inhibitor SANT-1 instead of CYC, the PCK activator PdbU instead of Indolactam V, 
the Notch inhibitor XXI instead of DAPT) and the addition of new factors able to 
increase Pdx1 and insulin expression, like TGF? and BMP pathways inhibitors (Alk5i 
and LDN193189), Thyroid hormone T3 or Betacellulin. With our new modified 
differentiation protocol, we obtain again an overexpression of all the keys genes and 
transcription factors characteristic of each stage of differentiation, but also, at the end of 
the differentiation process, an high percentage of insulin positive cells (14,23%) 
measured by flow cytometry. Terminally differentiated cells were able to secrete C-
peptide both in basal and stimulated condition, indicating that iPSC-derived pancreatic 
cells are able to secrete insulin in response to glucose.  
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Taken together, our data therefore confirm that: (i) iPSC can differentiate into insulin-
producing cells, (ii) pluripotent cell specification goes through the developmental stages 
of the embryo, (iii) the efficiency of the process, in terms of percentage of insulin-
positive cells at the final step, is comparable to that of ESC, (iv) human iPSC-derived 
pancreatic cells can engraft and survive in vivo at least for a short time. These data 
overall suggest that human iPSC have the potential to generate insulin-producing cells, 
that these differentiated cells can engraft and secrete insulin in mouse models, but a 
significant increase in differentiation efficiency and/or a strategy of selection of target 
cells before infusion is strongly needed. Moreover, also an efficient, low-cost and 
integration-free reprogramming strategy in GMP condition is fundamental for the 
translation to the clinical practice of an ideal personalized cell therapy for the cure of 
diabetes with pluripotent stem cells. 
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nostri lab meeting del martedì! 
Grazie a Paolo, il group leader più onnisciente del mondo. Sei l’unica persona che 
riesce a farmi ridere sempre, qualsiasi cosa accada e qualunque sia il mio umore, e non 
hai idea di quanto io ti sia grata per questo. 
Grazie alle isolologhe Alessia, Raffaella e Rita, per tutti i pellet, le isole, i consigli e i 
sorrisi che mi avete regalato in questi anni. 
Grazie anche a Vito, Cristina e Ilaria, formalmente non del nostro lab ma è come se lo 
foste. 
Dani, non mi sono dimenticata di te (e non ti sto escludendo dal gruppo del lab!), è solo 
che sei così importante da meritare una sezione a parte. Ringrazio sempre il giorno in 
cui Erica ha scelto te, perché lei ha trovato una grande ricercatrice, io una grande amica. 
E sono certa che qualsiasi strada decideremo di percorrere nella vita, la percorreremo 
insieme. You are my person.  
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Grazie anche a tutti gli “inquilini” del DRI, ognuno a modo suo parte integrante delle 
mio giornate. 
Un grazie “mega” va a Fra. Grazie per lo strano rapporto che siamo riusciti a creare in 
questi anni, perché nonostante tutto ci sei sempre stato. E so che potrò sempre contare 
su di te, qualsiasi cosa accada. 
Grazie a Sara, la mia salvezza spirituale in quest’ anno difficile! Grazie per il tuo 
immancabile ottimismo! 
Grazie Silvietta (e il piccolo Dani!) ed Andre, da 10 anni sempre accanto a me. 
Grazie a Giulie e Bla, le mie fecole preferite. Siete amiche speciali. 
Grazie anche ad Ale (finalmente sei tornato!), Elena (dai che arriverai presto anche tu a 
scrivere questa pagina!) e Nico (il mio futuro vicino di casa!). 
Grazie anche a quelle persone a cui dovrei dire tutto tranne che grazie, perché 
comunque mi sono servite a ricordarmi di quanto posso essere forte. 
Grazie alla mia famiglia, ai miei insostituibili genitori (e alla Happy ovviamente). 
Grazie per tutti i sacrifici che avete fatto per permettermi di arrivare a questo punto e 
per l’infinita pazienza che avete avuto nel sopportarmi nei miei momenti bui.  
Spero di avervi reso orgogliosi di me. 
All’interno della famiglia ringrazio anche Alessia, la mia sorella acquisita, che anche se 
è dall’altra parte del pianeta riesce a farmi sentire la sua presenza e ad essermi vicina 
come quando abitavamo nello stesso palazzo.  
E infine grazie all’unico vero Ragazzo della mia vita, Giuse. Non riesco neanche ad 
immaginare come sarebbe triste ora la mia vita se non ci fossimo mai incontrati. Da 
quando sei parte integrante della mia vita ho la certezza assoluta che non sarò mai sola, 
perché so che tu sarai sempre con me, pronto a starmi vicino come solo tu sai fare.  
E per quanto tu dica di dover fare il contrario, io mi auguro che non cambierai mai, 
perché sei semplicemente meraviglioso così come sei. GRAZIE. 
